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ABSTRACT 
Drug therapy for human immunodeficiency virus type 1 (HIV-1) infection often fails 
because of the appearance of resistant viral mutants. Thus knowledge on the abundance 
of resistant mutants prior to treatment is essential for optimizing drug therapy to avoid 
resurgence of resistant mutants. A simple multitype continuous-time branching process 
model is developed and investigated for the generation of resistant viral mutants during 
HIV-1 infection. The growth of mutant populations is characterized by means, variances 
and marginal distributions from the start of acute infection to equilibrium in the chronic 
stage. The expressions for the equilibrium frequencies of mutants are derived and their 
dependence on mutation rates and mutant fitness explored. The model suggests that 
mutants with three or more point mutations are unlikely to occur prior to treatment. A 
similar branching process model is also used to compute the number of resistant mutants 
that are generated de novo during treatment. Then the two possible causes of resistance-
related treatment failure are discriminated by characterizing the ratio of the amount of 
resistant mutants produced de novo to the number of preexisting resistant mutants. The 
ratio is determined by the fitness of mutants prior to treatment and the fitness of the 
wild-type virus and intermediate mutants during treatment. 
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CHAPTER 1. Introduction 
With more than 60 million infected, over 20 million dead by 2003 and 15,000 newly 
infected each day [JUN AIDS ( 2002)], it is obvious that HIV/ AIDS remains a serious 
problem across the globe. Since identification of human immunodeficiency virus type 
1 (HIV-1) as the causative agent of acquired immune deficiency syndrome (AIDS) in 
1983 [Barr&Sinoussi et al. (1983), Gallo et al. (1983)], significant research has been 
conducted to learn more about the virus [Fauci (2003)]. Currently, our best weapons 
against HIV-1 are drugs that inhibit virus growth in infected patients, particularly when 
applied in combination. However, several unique characteristics associated with HIV-1 
infection, including the existence of latent reservoirs and the virus' high replication and 
mutation rate, can make combination therapies ineffective. One major obstacle is the 
emergence of resistant viruses that decrease the efficacy of currently used therapies [Gal-
lant (2000)]. 
To optimize drug therapy for HIV-1 infection, it is essential to know how soon drug-
resistant mutants are appearing and how many are present in the patient at the start 
of treatment. It is also important to differentiate the two possible causes of resistance-
related treatment failure - resistant mutants that preexist in the patient prior to treat-
ment or resistant mutants that are generated de novo from residual replication during 
treatment - because they require different treatment strategies. Currently available ex-
perimental methods are generally too insensitive to detect the existence and numbers of 
all HIV-1 resistant isolates. The process of viral mutant production, however, is based on 
simple and precise principles: mutation followed by selection. Therefore, mathematical 
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models can help distinguish between these two possibilities. 
Deterministic approaches have been used extensively to model HIV-1 infection within 
individuals [Perelson et al. (1999), Nowak et al. (2000), Perelson (2002)], including 
the generation of resistant mutants prior to treatment [Ribeiro et al. (1998)] and during 
antiretroviral therapy [Ribeiro et al. (2000)]. While such models, mainly systems of or-
dinary differential equations (ODEs), are appropriate for large populations of replicating 
viruses where mass-action laws dominate, they may not describe the random fluctuations 
or extinctions observed in small populations [Brown (1997), Brown et al. (1997)]. The 
mutant viruses generated before treatment or early after treatment will initially exist in 
small populations of this kind. A few stochastic models have been formulated to inves-
tigate the random nature of primary infection [Merrill (1989), Tuckwell et al. (1998), 
Tan et al. (1998), Wick et al. (2000), Kamina et al. (2001)] and quantify the probabil-
ities that resistant mutants preexist [Frost et al. (2000)] or emerge de novo during drug 
therapy [Ribeiro et al. (2000)]. 
In this thesis, I use stochastic branching process models to investigate the genera-
tion of drug-resistant mutants in drug nai:ve patients and to compare the chance that 
resistance-related treatment failure is caused by preexistence of resistant mutants or de 
novo resistance generated during treatment. This thesis takes the traditional format 
with the references for all chapters collected in the bibliography. I begin Chapter 2 by 
summarizing the biology and treatment of HIV-1 infection. A basic population model of 
HIV-1 primary infection is explained for historical reasons and will be used in Chapter 
4 to divide the course of primary infection into two stages. In Chapter 3, I review the 
numerical methods for multitype continuous-time branching processes with independent 
Poisson immigration that will be used to explore the stochastic model for HIV-1 mutants 
developed here. Chapter 4 lays out a basic branching process model for the generation 
of mutants and uses this model to explore the properties of mutant populations prior to 
and during treatment. 
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CHAPTER 2. Review: HIV-1 Infection, Treatment, Drug 
Resistance, and Dynamics 
2.1 Molecular Virology and Life Cycle of HIV-1 
HIV-1 is a retrovirus, with an RNA genome that is transcribed into DNA during its 
life cycle. The nucleotide sequence of the HIV-1 genome was determined in 1985 [Ratner 
et al. (1985), Wain-Hobson et al. (1985), Sanchez-Pescador et al. (1985)], just over one 
year after identification of HIV-1 as the causative agent of AIDS. The genome of HIV-1 is 
about nine kilobases with nine genes in distinct reading frames, which together encode 
at least fifteen viral proteins [Frankel et al. (1998)]. There are two structural genes 
called gag and env. The gag gene encodes for a polypeptide which is cleaved by the HIV 
protease into four subunits, matrix, capsid, nucleocapsid, and p6. These subunits form 
the coat that encloses the genetic material of the virus. The env gene encodes two viral 
envelope proteins called gp41 and gp120. Gp41 is a transmembrane protein embedded in 
the membrane of the HIV-1 particle and gp120 is attached to gp41 on the external face 
of the viral membrane. Both gp120 and gp41 are essential for the entry of virus into the 
host cell. Gp120 mediates binding of the virus to CD4 and chemokine receptors, while 
gp41 mediates the fusion of viral and host cell membranes. The essential enzymes of the 
virus, including reverse transcriptase, protease, and integrase, are encoded by the pol 
gene. The reverse transcriptase copies the viral RNA into DNA. The protease cleaves 
the gag and gag-pol gene product and the integrase helps to insert the viral DNA into the 
genome of the host cell. In addition to the gag, pol and env genes, there are six regulatory 
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genes, which encode the regulatory proteins, Tat and Rev, and the accessory proteins, 
Nef, Vpr, Vif, and Vpu. These proteins control viral replication by manipulating the 
regular cellular machinery. 
The main target of HIV-1 is the CD4 T helper cell, a critical part of the body's im-
mune system. HIV-1 begins its infection of a susceptible host cell with binding of gpl20 
to the CD4 receptor on the host cell [Dalgleish et al. (1984), Klatzmann et al. (1984)]. 
This initial binding triggers conformational changes that promote binding to a secondary 
receptor called a chemokine receptor [Doms et al. (2000), Kwong et al. (1998)]. There 
are different variants of HIV-1 virus that use different chemokine receptors [Scarlatti 
et al. (1997)]. Other antigen-presenting cells with CD4 and chemokine receptors, e.g., 
macrophages and dendritic cells, are also infected by HIV-1. 
The next step of infection is gp41-mediated fusion of viral and cellular membranes. 
Interaction of gpl20 with CD4 and chemokine receptors induces a conformational change 
in gp41 in preparation of viral entry [Chan et al. (1998)]. After being released into 
the cytoplasm, the viral core is uncoated and transforms into the reverse transcription 
complex, the Vif-stabilized machinery responsible for reverse transcribing viral genome 
into cDNA through action of the HIV-1 reverse transcriptase [Karageorgos et al. (1993)]. 
Each virion contains two copies of the RNA genome. During reverse transcription, 
reverse transcriptase jumps frequently from one molecule to the other and produces 
a DNA molecule that is a recombination product of the two RNA molecules [Coffin et 
al (1997)]. The homologous intermolecular recombination rate is estimated to be 4x10-5 
per base per replication cycle [Hu et al. (1990)]. Due to the lack of a proofreading and 
repair mechanism, the spontaneous error rate of reverse transcription is high, also at 
order of 10-5 per base per replication cycle [Mansky et al. (1995), Mansky et al. (1996)]. 
This is one main cause of drug resistance (see Section 2.4) and immune escape. 
After reverse transcription, an HIV-1 preintegration complex, including the double-
stranded viral cDNA, viral integrase and other accessory proteins, forms [Miller et 
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al. (1997)) and enters the cell nucleus through nuclear pores. Once in the nucleus, 
the newly synthesized viral DNA can be integrated into the chromosome of the cell in 
a reaction catalyzed by the viral integrase [Farnet et al (1996)]. The viral DNA may 
also experience joining, homologous recombination or self-integration and form circular 
structures, none of which will yield infectious virus. The activity of the integrated viral 
genome, or provirus, depends on the locations of integration, viral factors, cellular fac-
tors and activation state of the host cell. When viral replication is rapid and efficient, 
the host T cell is called a productively infected T cell (PIT). The provirus may also 
persist in a latent state in a resting CD4 T cell for many years [Pomerantz et al. (1992), 
Li et al. (1996), Chun et al. (1997)), which may involve both transcriptional and post-
transcriptional mechanisms [Hermankova et al. (2003)). The ability of HIV-1 provirus 
to persist in latently infected cells is a major barrier to eradication or cure of HIV-1. The 
reservoir of latent provirus supplies the virus that rapidly resurges after antiretroviral 
therapy is terminated [Chun et al. (1999), Chun et al. (2000)). For this reason, based 
on our current knowledge, patients must remain on anti-viral therapy for life [Blankson 
et al. (2002)]. 
An actively infected cell (PIT if T cell) is actively transcribing proviral DNA into 
RNA. Some of these RNA molecules are incompletely spliced or unspliced and encode 
the viral structural enzymatic accessory proteins and viral genome. Others are multiply 
spliced and encode the regulatory proteins Tat, Rev and Nef. Tat is a transcriptional 
activator which mediates the activation of latent HIV-1 provirus; Rev is a shuttling pro-
tein which facilitates export of the incompletely spliced or genomic RNAs from nucleus 
to cytoplasm; Nef may alter the conditions of host cells in a way that promotes the 
production and release of more infectious virus. 
The precursor Env protein is expressed and cleaved in the endoplasmic reticulum into 
viral envelope proteins gp41 and gp120. Vpu and Nef prevent premature association of 
gp41 and gp120 with CD4 by promoting degradation of CD4. The viral RNAs and 
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proteins assemble at the plasma membrane where budding occurs. After release of 
viral particles, Gag and and Gag-pol polyproteins are cleaved by viral protease [Kohl et 
al. (1988), Peng et al. (1989)] and then the particle becomes mature and infectious. The 
host cells die from cytopathic effects of virus or immune-mediated cellular destruction. 
Bystander cell apoptosis may also be induced through indirect mechanisms of viral 
cytopathogenicity [Stevenson ( 2003)]. 
Unless the HIV-1 life cycle is interrupted by treatment, the virus infection is dissem-
inated throughout the lymphatic tissues and slowly depletes the body's immune system 
of CD4 T cells over a period of years. The advanced stage of HIV-1 infection, AIDS, is 
characterized by a CD4 cell count < 200 cells per µl, and the average time from primary 
infection to AIDS is 10 years in the untreated patient. 
2.2 Current Treatment of HIV-1 Infection 
Several medications have been designed to combat HIV-1 infection by targeting the 
vulnerable steps in the life cycle of HIV-1 infection [Pomerantz et al. (2003)]. These 
drugs fall into three categories according to the step in the HIV-1 life cycle they target 
- reverse transcriptase inhibitors, protease inhibitors, and fusion and entry inhibitors. 
Inhibitors of reverse transcriptase were the first anti-HIV medications and are still 
a critical part of current treatment regimens. Nucleotide analogue reverse transcriptase 
inhibitors (NRTis), like zidovudine (AZT), are structurally similar to nucleosides and ter-
minate the DNA chain when incorporated into elongating DNA stands. Non-nucleoside 
reverse transcriptase inhibitors (NNRTis), like nevirapine, work through noncompetitive 
binding to reverse transcriptase. These drugs bind to a pocket near the active site of 
the enzyme, result in a conformational change of the active site, and thereby prohibit it 
from efficiently catalyzing the transcription of viral RNA. 
Protease inhibitors (Pis) are designed to block the function of HIV-1 protease, again 
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unique to the virus. Pis bind to the active sites of viral protease and prevent cleavage 
of the Gag and Gag-pol precursor proteins, which is required for the production of new 
and infectious virus particles [Flexner (1998)]. 
Fusion inhibitors block the fusion of the viral envelope to the cell membrane by pre-
venting the conformation change of gp41 required for fusion. The first fusion inhibitor, 
enfuvirtide (Fuzeon), was approved by the FDA in March 2003 [Burton (2003), Lalezari 
et al. ( 2003)]. Other small chemicals are under research to block the binding of virus 
and chemokine coreceptors also required for entry of virus into the cell [Donzella et 
al. (1998)]. 
Inhibitors of viral integrase are currently in the human clinical trial stage [Hazuda 
et al. (2000), Nair (2002)]. A number of new drugs are under research to target Tat 
transactivation [Chao et al. (2000), Lind et al. (2002)] and Rev-dependent export of 
viral transcripts from nucleus to the cytoplasm [Wolff et al. (1997)]. 
Monotherapy, i.e., the treatment with a single drug, usually results in a rapid decline 
of plasma virus load and an increase in the CD4 cell count [Wei et al. (1995), Ho et 
al. (1995), Schuurman et al. (1995), Nowak et al. (1995), Loveday et al. (1995)]. 
However, the effect of monotherapy is short-term and drug-resistant virus mutants can 
emerge rapidly in a few weeks (or months). 
Management of HIV-1 infection has greatly improved because of the development 
of new treatment protocols called highly active antiretroviral therapy (HAART), that 
combine three or more highly potent drugs. Currently the national guidelines on AIDS 
treatment policy indicate that all patients should be treated with a combination of 
drugs from different categories to maximize suppression of HIV-1. Combining lamivu-
dine, zidovudine and one (or two) protease inhibitors can reduce virus load by more 
than 10000-fold [Perelson et al. (1997), Lafeuillade et al. (1997)]. Successfully treated 
patients have no detectable plasma virus ( <50 RNA copies per ml), declining levels of 
infectious HIV-1 in peripheral blood mononuclear cells and slowly declining levels of 
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HIV-1 DNA provirus, accompanied by the regeneration of CD4 T cells. The duration of 
the suppression can be as long as 4 years [Gulick et al. (2000), Sterling et al. (2003)]. 
AIDS has been transformed from a highly fatal disease into a chronic and somewhat 
manageable disease in developed countries where the antiretroviral medication is ac-
cessible [Pomerantz et al. (2003)]. However, combination therapy is not effective in 
all patients and may fail because of serious side effects, poor adherence to the therapy 
protocol, or emergence of resistant virus [Cohen (2002)]. 
2.3 Occurrence of Drug Resistant Viral Mutants 
HIV-1 is known to be a highly variable virus. Its high genetic variability stems from 
two main sources: the high error rate of reverse transcriptase and the rapid turnover 
rate. 
Due to the lack of a 3'-exonuclease activity, reverse transcriptase transcribes vi-
ral RNA into DNA in a highly error-prone fashion [Wain-Hobson et al. (1989), Man-
sky (1998)], with a mutation rate on the order of 10-5 per base per round of replica-
tion [Mansky et al. (1995), Mansky et al. (1996)]. 
The high error rate of reverse transcriptase is augmented by the rapid turnover rates 
of virus and infected cells. Rapid turnover can make the virus remarkably sensitive to 
any agent that efficiently inhibits any step of the viral life cycle. Analyzing the decay 
kinetics of the viral load in peripheral blood after administration of potent antiviral 
drugs demonstrated that most HIV-1 particles detected in peripheral blood are only a 
few hours old, recently produced by cells that themselves were infected only 1 or 2 days 
earlier [Coffin (1995), Perelson et al. (1996), Ho et al. (1995), Wei et al. (1995)]. It 
was estimated around 109 - 1010 new virus particles are produced per day. Considering 
the rapid mutation rate, the number of new single nucleotide mutations generated per 
day is on the order of 104 - 105 • 
9 
The impact of such single mutations on the level of resistance can be very different 
among drugs. Indeed, while single mutations can confer high-level resistance to a nucle-
oside analog such as 3TC (lamivudine) or to some of the NNRTis, it takes the stepwise 
accumulation of several mutations to confer full resistance to most Pis or AZT. 
There are two possible scenarios leading to resistance related treatment failure [Ribeiro 
et al. (2000)]. Either preexisting resistant strains are selected by the drug or resistant 
mutants are generated de novo by residual virus replication during treatment. It is im-
portant to distinguish between these processes, because they require different combative 
strategies. If drug failure is more likely to be caused by the preexisting resistant mutants, 
then a drug combination with a diverse resistance profile is needed. On the other hand, 
the aim of treatment should be to minimize the residual replication during treatment if 
drug failure is more likely to be caused by the de novo generated resistant mutants. 
Both phenotypic and genotypic assays have been proposed to test the existence of 
HIV-1 resistant isolates. However, due to the quasispecies nature of HIV-1, innumerable 
variants may exist in an infected individual and current methods are not sensitive enough 
to detect minor populations of drug resistant mutants [Shafer (2002)]. 
2.4 Dynamics of HIV-1 Infection 
Nowak et al. (1996) and Bonhoeffer et al. {1997c) described a basic model of virus 
dynamics during primary infection 
:i; - A. - dx - {3xv, 
y - (3xv - ay, 
V - ky- UV. 
(2.1) 
Their model considers dynamics of three populations: uninfected cells, x, infected cells, 
y and free virus particles, v. Uninfected cells are produced from a precursor source 
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such as the thymus at a constant rate, >., and die at rate d per cell. Uninfected cells 
become infected through interactions with virus. The infection rate is proportional to 
the abundance of uninfected cells, x, and free virus, v, with rate constant /3. Infected 
cells die at rate a per cell. The death might involve viral cytopathic effects or immune-
mediated cellular destruction [Stevenson (2003)]. Free virus is produced from infected 
cells at rate k per cell and cleared at rate u per virus. 
In the absence of infection, the system of nonlinear differential equations reduces to 
a single linear ODE x = >. - dx, and the abundance of uninfected cells at equilibrium is 
>./ d. Hence, with initial conditions x0 = >./ d, y0 = 0 and v0 , we can numerically solve 
the differential equations and obtain approximate solutions of the system. The crucial 
quantity is the basic reproductive ratio, Ro, which is defined as the number of newly 
infected cells that arise from any one infected cell when all cells are uninfected. The 
equation for Ro is given by 
Ro= /3>.k. 
adu (2.2) 
When Ro > 1, the infected cells and free virus will show an exponential growth 
phase followed by a peak and subsequent decline to an equilibrium. The equilibrium 
abundance of uninfected cells, infected cells and free virus is given by 
x* 
au Xo 
= - Ro' /3k 
y* 
>. du du 
(2.3) = - - - =(Ro - 1)-
a /3k /3k' 
v* 
>.k d d 
- du - 73 =(Ro - l)73· 
This equilibrium state corresponds to the chronic stage of HIV-1 infection. The av-
erage time from primary infection to diagnosis of AIDS is ten years and the plasma viral 
load in a patient with chronic HIV-1 infection generally remains unchanged. Equilibrium 
abundances give us few insights about the dynamics of HIV-1 infection, but the arrival of 
potent antiretroviral drugs allowed researchers to study the equilibrium with perturba-
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tion and obtain estimates for the parameters of viral dynamics [Wei et al. (1995), Ho et 
al. (1995), Perelson et al. (1996)]. Reverse transcriptase inhibitors prevent virus from 
infecting new cells, while protease inhibitors cause production of non-infectious virus 
particles. Let w denote the non-infectious virus particles, then the basic model (2.1) is 
transformed to 
x = >. - dx - (1- eRT)f3xv, 
ii = (1- eRT)f3xv - ay, 
V = (1- ePI)ky - UV, 
w = ep1ky - uw, 
where eRT and ep1 are the efficacies of reverse transcriptase and protease inhibitors. For 
example, if perfect protease inhibitors are used above, eRT = 0, ePT = 1, and we assume 
x is approximately constant during the time considered, then the viral decay, including 
both infectious and non-infectious virus, is given by 
uv* uv* v(t) + w(t) = v*e-ut + --[--(e-at - e-ut) - ate-ut]. 
u-au-a 
Fitting clinically observed viral load decays in patients to the above equation gave esti-
mates for the parameters u and a and revealed extremely fast viral dynamics [Perelson 
et al. (1996)]. 
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CHAPTER 3. Review: Numerical Methods for Multitype 
Continuous-Time Branching Processes with Independent 
Poisson Immigration 
3.1 Introduction 
The theory of branching processes was first introduced by nineteenth century demog-
raphers studying the extinction of noble family names in England [Watson et al. (1874)] 
and has developed and matured significantly since then [Harris (1963), Feller (1968), 
Mode (1971), Athreya et al. (1972), Karlin et al. (1975), Asmussen et al. (1983), Rahi-
mov (1995)]. In the twentieth century, problems in biology and medicine both inspired 
and showcased the growing theory of branching processes [Fisher (1930), Fisher (1958), 
Haldane (1927), Jagers (1975), Kimmel et al. (2002)]. For example, population bi-
ologists used the branching process to model genetic drift in a population, and mathe-
matical epidemiologists built models of cancer where precursor cancer cells either grow 
uncontrolled to establish a tumor or harmlessly go 'extinct'. The same pattern in HIV-1 
proliferation was first noted by Merrill (1989) and then Wick et al. (2000). 
Some numerical methods for multitype continuous-time branching processes with 
independent Poisson immigration were recently surveyed and extended by Dorman et 
al. (submitted), with one of their examples concerning HIV-1 resistance within a single 
patient. A multitype process allows us to model cells infected by different viral mu-
tants. The continuous-time model better accommodates variability in particle lifetimes 
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and immigration of particles. Much is gained by making the realistic assumption that 
new mutations occur according to a Poisson process [Bartlett et al. (1960), Karlin et 
al. (1975), Kaplan et al. (1995)]. Allowing inhomogeneity in immigration rates enables 
us to investigate the populations of viral mutants generated from nonequilibrium popu-
lations of wild type virus. In this chapter, we summarize the main results in Dorman et 
al. (submitted) and supplement with details most relevant to our model. 
3.2 Definition of Multitype Branching Process 
A multitype branching process considers the growth of a population of independently 
acting particles consisting of r < oo categories. In Chapter 4, the different categories will 
correspond to the CD4 T cells infected by different HIV-1 mutants. With each category, 
we associate two random entities capturing the stochastic nature of the particle's life 
time and reproduction. 
For the continuous time process, we assume that a type i particle has an exponentially 
distributed life time with death rate wi, i.e., the average life time of a type i particle is 
l/wi. The lack of memory property of the exponential distribution guarantees that a 
process so defined is Markovian. The Markovian assumption limits applicability of the 
model, but it is certainly no less realistic than the alternative of fixed lifetimes assumed 
in discrete-time branching processes. 
The reproduction of a particle of type i is summarized by its progeny generating 
function 
~(s) = L PinSn = L Pinsf1 • • • s~r, (3.1) 
n~O n~O 
using the row vector s = [si, ... , sr], si E [-1, 1], and multi-index n = [n1, ... , nr], 
ni ~ 0. The coefficient Pin is the probability that a type i particle gives birth to ni 
particles of type j for 1 ~ j ~ r at end of its life. 
Let the particle count at time t be Zt = [Zn, ... , Ztrl· Probability generating June-
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tions play important roles in finding moments and understanding the distribution of Zt. 
Define 
Qi(t,s) = E(sZtlZo = ui) = L PiztSzt = L PiztS~n · ··s~tr, (3.2) 
Zt~O Zt~O 
wheres is as above, Pizt = Pr[Zt = ZtlZo = ui] and Ui is the unit vector with all entries 
0 except for a 1 at position i. For notational convenience, we will use the abbreviations 
Q(t,s) - [Q1(t,s), ... ,Qr(t,s)], 
P(s) = [P1(s), ... , Pr(s)]. 
Let fij = 8~. Pi ( 1), 1 = [ 1, ... , 1], be the expected number of type j daughter particles 
1 
produced by a particle of type i. Define the r x r matrix n whose entries nij = Wi(jij -
li=j)· Typically n is irreducible with one algebraically simple, real eigenvalue >. with 
left and right eigenvectors having positive entries. Any other eigenvalue () of n satisfies 
Re( B) < >.. The process is classified as subcritical, critical, or supercritical according to 
whether >. is negative, zero or positive, respectively. 
We can formulate a branching process by modeling reproduction as a birth-death 
process. Suppose in a birth-death process, a type i particle experiences death at rate 
µi and reproduction of daughter particles of type j at rate >.ii. We can construct a 
branching process from this birth-death process as follows. 
Because the host cell normally does not die with each release of a virus, we view the 
mother particle as dying at each reproduction event and being replaced by an identical 
substitute. Reproduction continues until one of the substitutes dies an ordinary death. 
Let >.i = 2:.f =1 >.ii. Then the corresponding branching process has Wi = µi + >.i and by 
Eq. (3.1) the progeny generating function for a type i particle is 
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For calculating the variance, we will also need the progeny means 
, 1 ~ i,j ~ r, 
and the progeny Hessian matrix for a particle of type i 
0 if j =f i, k =f i 
a2 ~(1) ~ if j =f i, k = i 
(Hi)ik µ;+A; , 1 ~ j,k ~ r. - 8s;8sk ~ if j = i, k =f i µ;+A; 
~ if j = i, k = i µ;+A; 
The covariance matrix of the progeny generating function Pi(s) is calculated by formula 
Gi = Hi + diag(fi) - ftf;,. (3.4) 
I 
where fi = [fil, ... , fir]· 
3.3 Some Miscellaneous Results 
Before proceeding, we list some results that will be used later. 
3.3.1 Product Formula for Probability Generating Functions 
For independent random vectors X and Y 
(3.5) 
If a process starts from initial vector Z0 = [ni, ... , nr], then by the additive property, 
{Zt; t 2'.: O} is the sum of n 1 + · · · + nr independent processes, ni of which are initiated 
from state Ui, 1 ~ i ~ r. By Eq. (3.5), the probability generating function for the 
process is 
r 
II Qi(t,sr. (3.6) 
i=l 
16 
3.3.2 Poisson Processes and Campbell's Formula 
Since we are considering the branching processes with independent Poisson immi-
gration, we also record some results for Poisson processes [Kingman (1993)], that will 
facilitate later derivations. 
A Poisson process defines a random countable set of points II on some measurable 
space 0 equipped with au-finite measure v. If A is a measurable subset of 0, then the 
counting variable 
NA= #(IInA) 
is either finite with probability 1 or countably infinite with probability 1, depending on 
whether v(A) is finite or infinite. In the former case, NA follows a Poisson distribution 
with mean v(A). To complete the formulation, we assume that measure v has no point 
mass and that any finite collection {Ai, ... , Ak} of disjoint measurable sets of 0 generates 
a collection { N Ai, ... , N Ai.} of independent counting variables. 
Campbell's theorem deals with random sums of the sort 
8= L J(X), 
XEII 
where the real-valued function f : 0 --+ R is measurable and X is a generic point of II. 
It can be shown that the random sum defining S converges absolutely with probability 
1 if and only if 
k min{lf(x)I, l}dv(x) < oo. (3.7) 
If this condition holds, then 
E(e88 ) = exp{k (e8f(z) - 1) dv(x)} (3.8) 
for any complex (} for which the integral on the right converges, and in particular when-
ever (} is pure imaginary. 
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Expanding both sides of Eq. (3.8) as power series in(}, 
fJ2S 2 E(S2 ) 
LHS = E(l+Os+21+···)=l+OE(S)+02-2-+···; 
1 ( fJ2j(x)2 ) (J0 (0j(x) + 821it>2 + ·· ·)dv(x))2 RHS = 1 + Bj(x) + + · · · dv(x) + + · · · n 2! 2! 
= 1 + (J lo f(x) dv(x) + 82 ~[lo j(x) 2 dv(x) + (lo f(x) dv(x) YJ + · · ·, 
and equating coefficients of(} and 02 , we get some useful results. Notably, 
E(S) = k f(x) dv(x), 
Var(S) = k f(x) 2 dv(x). 
Take(}= iu in Eq. (3.8), we obtain the characteristic function of S 
(3.9) 
If J(x) takes nonnegative integer values, then we take(}= logu in Eq. (3.8) and obtain 
the probability generating function of S 
for any u for which the equation converges. 
More generally, if Ji, ... , fn are n functions satisfying condition (3.7), then the ran-
dom sums Si = Z:xEII fi(X), 1 :::; i :::; n, converge absolutely and the joint characteristic 
function is 
(3.10) 
for all (}i imaginary. Again, the joint generating function 
E(IJ uf') = exp{kllJ u{i(x) - 1] dv(x)} 
i i 
(3.11) 
is defined when all fi are nonnegative and integer valued. If in addition the Ji satisfy 
the conditions In fi(x) 2 dv(x) < oo, then the covariance between the sums reduces to 
(3.12) 
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The marking theorem for the Poisson process figures prominently in dealing with 
branching processes. In marking, we suppose there is a second measurable space r of 
possible marks for each point x E 0. For each random point X = x E II, a mark y E f is 
independently assigned by sampling from a distribution p(x, ·)on r. If the distributions 
p(x, ·) are compatible in the sense that x ~ p(x, B) is measurable for each measurable 
B c r, then we get a Poisson process on the product space n x r with intensity measure 
1(C) = JJ p(x, dy) dv(x) 
(x,y)EC 
The marking theorem will allow us to compute certain branching process moments and 
probabilities with great ease via Campbell's theorem. 
3.3.3 Vee Operator and Kronecker Products 
The Vee operator stacks the successive columns of a matrix to form a column vector. 
If A = ( aii) is an k x l matrix and B = ( bii) is an m x n matrix, then the Kronecker 
product A® B is the km x Zn block matrix 
A®B= 
Three identities that will be used later are 
(i) If C is a n x p matrix, then 
Vec(ABC) = (C* ® A)Vec(B). (3.13) 
(ii) For two finite sequences of column vectors vi and wi related by wi = Avi, the 
vectors wand v produced by stacking satisfy 
w = (l®A)v (3.14) 
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for an identity matrix I of the correct dimension. 
(iii) If wi =Li aiivi, then stacking yields 
w = (A@I)v. (3.15) 
3.4 Calculation of Moments 
3.4.1 Calculation of Means 
Let m(t) = [m1(t), ... , mr(t)] be the mean vector of Zt. It is well-known that 
m(t) = m(O)etn without immigration of particles. In the presence of immigration, we can 
calculate m(t) by deriving forward differential equations and then solving [see Dorman 
et al. (submitted)]. Derivation via marking and Campbell's theorem is listed here 
I 
because this method will be used again in the calculation of the variance and probability 
generating function of Zt· 
We suppose type i particles are immigrating according to independent Poisson pro-
cesses with rates 'T/i(t), 1 ~ i ~ r. For the sake of simplicity, temporarily assume that 
we start with no particles and only type i particles can immigrate. Let T E [O, t] de-
note a Poisson time of immigration and we mark the immigrant with the vector of its 
descendants YT E N0 at time t, where N0 is the set of r-dimensional vectors with non-
negative integer entries. The marking theorem implies that we get an induced Poisson 
process, say IIm, on the product space [O, t] x N0. The intensity measure has density 
'ffi(r)Pin(t - r). Then Zt reduces to the random vector sum 
Zt = L YT 
(T,YT)ETim 
over the points (T, YT) of the marked Poisson process IIm. By formula (3.9), 
IDi(t) = E(Zt) = 1t L llPin(t - r)17i(r) dr 
O n2:0 




When the rates of immigration 'IJi(t) = aief3;t are exponential, 
Illi(t) - rt aie{J;r Uie(t-r)O dT = rt laiu!uie{J;rle(t-r)O dT lo lo i 
= laiu;lli fat er(f3;I-O) dretn = laiu;ui(n - .8il)-1(em - etf3;I) 
provided no .Bi is an eigenvalue of n. Finally, when the process Zt starts with initial 
counts m(O) and as above, immigration of type i particles is occurring with rates 'IJi(t) = 
aief3;t for 1 :::; i :::; r, the mean vector of Zt is given by 
r r 
m(t) = m(O)etn + L mi(t) = m(O)etn + 1 L aiu;ui(n - .Bi1)-1(et0 - etf3;1). (3.18) 
i=l i=l 
This formula is readily extended to the case 'IJi(t) = ai1ef3Ht + ... + awef3wt = 
E~=l aidef3;dt, a linear combination of exponential functions. In this case, 
r D 
m(t) = m(O)etn + 1 L u;ui L aid(n - .8id1)-1(etn - etf3;d1). (3.19) 
i=l d=l 
For example, if 17i(t) = ai cos( bit)+£;, we can substitute cos( bit) = (eAM +e-Ab;t)/2 
and use formula (3.19). For the general immigration rate 'IJ(t) where there is no analytic 
integral in (3.17), we can approximate 17(t) using a linear combination of exponential 
functions and apply Eq. (3.19). 
For asubcritical process with immigration rates converging to constants 'I]= [ry1 , ... , 'IJr], 
a stochastic equilibrium is reached between extinction and immigration. Taking limits 
in Eq. (3.18), we obtain the mean vector at equilibrium as 
r 
1 I: TJiu;llin-1 = -ryn-1. (3.20) 
i=l 
3.4.2 Calculation of Variances 
Let Vi(t) = E(Z;Zt)-E(Zt)* E(Zt) be the covariance matrix for the process Zt start-
ing from Z0 = ui. A forward differential equation can be derived and solved [Athreya 
et al. (1972), Lange (1982), Dorman et al. (submitted)]. The sketch of derivation 
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by Dorman et al. (submitted) is given here. By a standard argument, 
r 
Vi(t + T) = Var[E(Zt+rlZt)) + E[Var(Zt+rlZt)) = Var[Zter11) + E[L Zti Vi(T)] 
j=l 
r r 
= (er11)*Vi(t)ern + L mii Vj(T) = ern•vi(t)ern + L mii[Vj(T) - Vi(O)], 
j=l j=l 
which can be turned into 
r 
Vec[Vi(t + 7)] = (ern• ® er0*)Vec[Vi(t)) + L mijVec[Vj(T) - Vj(O)) 
j=l 
by the Vee operator and formula (3.13). Forming the difference quotient and sending T 
to 0 yields 
d 
dt Vec[Vi{t)J 
1 • • r 1 
lim -{e ... n © e ... n - I© I)Vec[Vi(t)] + '°" mi;Vec[lim -{Vj{r) - Vi{O)}] r-or L.J ... -or 
j=l 
r d 
(S1* ©I+ I© S1*)Vec[V;(t)J + L m;j(t)Vec[-d Vj{O)]. 
I j=l t 
Let Ci = ft Vi(O), 1 ~ i ~ r. Stacking vectors Vec[Vi(t)] and Vee( Ci) into vectors 
Vec[V(t)) and Vec(C), substituting etn for [mij(t)), and employing formulas (3.14) and 
(3.15), we obtain 
d 
dt Vec[V(t)) =I® (O* ®I+ I® O*)Vec[V(t)] + (etn ®I® I)Vec(C). (3.21) 
Dorman et al. (submitted) shows that (3.21) has unique solution 
and Ci is given by 
C. = .!!:_ V·(O) = w·(G· + u!n. + f''f. - u!f. - en.) i dt i i i i ...ai i i i i i ...ai • 
When the matrix 0 is diagonalizable as A/J.A - 1, the integral can be explicitly eval-
uated 
Vec[V(t)] H (lot ert:i. ® e(t-r)t:i. ® e(t-r)t:i. dT) H-1vec(C) (3.22) 
- HX(t)H-1Vec(C) 
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where H =A® (A*)-1 ® (A*)-1 and X(t) = J~ erA ® e<t-r)A ® e<t-r)A dr. The n3 x n3 
matrix X(t) is diagonal and its diagonal entry at level m = (i - l)n2 + (j - l)n + k is 
kt e6;t _ e<6;+61c)t [X(t)]m,m = er6;e(t-r)6;e(t-r)6,, dr = ' 
0 8i - 8; - 8k 
where 8i, 1 ~ i ~ r, is the ith diagonal entry of b.. 
In the presence of immigration, evaluation of Var(Zt) proceeds via marking and 
Campbell's theorem. For the sake of simplicity, temporarily assume that we start with 
no particles and only type i particles can immigrate. Recall Zt is the random vector 
sum (3.16) over the points (T, YT) of the marked Poisson process Ilm. By formula (3.12), 
Wi(t) = Var(Zt) =lat E(Y;Yr)Pin(t- r)1Ji(r)dr =lat E(Y;,YTIT = r)1Ji(r)dr 
0 n?O 0 
- lot 1Ji(r)[Vi(t - r) + E(Y;.IT = r)E(Y TIT= r)] dr 
- lot 1Ji(r)[Vi(t - r) + e<t-r)O* u;Uje<t-r)O] dr. 
By (3.13), stacking the columns of Wi(t) produces 
Vec[Wi(t)] =lot 1Ji(r){Vec[Vi(t - r)] + e<t-r)O* ® e<t-r)O*Vec(u;ui)} dr. 
Let Vo = (uiu1lu2u2I · · · lu~Un) be then x n2 matrix with then matrices U:11i, 1 ~ 
i ~ r, arranged horizontally. When 0 is diagonalizable as Ab.A - 1, further stacking by 
identities (3.14), (3.15) and (3.23) produces 
Vec[W(t)] = lot {diag[17(r)] ®I® I} 
where 
x {Vec[V(t - r)] + [I® e<t-r)O* ® e<t-r)O*]Vec(V 0)} dr 
= lot {diag[17(r)] ®I® I}{Vec[V(t - r)]} dr 
+lot {diag[17(r)] ® e<t-r)O* ® e<t-r)O*} drVec(Vo) 
= F(t)Vec(C) + G(t)Vec(V 0), 
F(t) - lot {diag[17(r)] ®I® I}HX(t - r)H-1 dr; 
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G(t) = lot {diag[77(r)] ® e(t-r)n• ® e(t-r)n*} dr. 
When 'r/i(t) = aief3;t, we write F(t) as a sum and implement a change of variable 
F{t) = f)u;ui ®I® I) 1t 'r/i(r)HX(t - r)H-1 dr 
i=l 0 
- f)u;ui ®I® I)H[fnt 'f/i(t - r)X(r) dr]H-1 
i=l 0 
n 
- ~)u;ui ®I® I)HZi(t)H-1, 
i=l 
where 
We can define a n4 x n4 diagonal matrix Z(t) with matrices Zi(t) along the diagonal 
I 
and the diagonal entry at level m = (i - l)n3 + (j - l)n2 + (k - l)n + l is 
[Z(t)]m,m = 
{3.23) 
To calculate G(t) when n is diagonalizable, we note 
G(t) - fot[I ® (A*)-1 ® (A*)-1]{diag[77(r)] ® e(t-r)ti ® e(t-r)t.}[I ®A*® A*] dr 
- JY(t)J-1 , 
where J =I® (A*)-1 ® (A*)-1 and Y(t) = JJ diag[77(r)] ® e(t-r)t. ® e(t-r)t. dr. Y(t) is 
diagonal and the diagonal entry at level m = (i - l)n2 + (j - l)n + k is 
Now we are able to calculate both Vi(t) and Wi(t) for 1 S i S r, assuming n 
diagonalizable and Poisson immigration with rate aief3;t. Again, these formulas are 
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readily extended to the case where the immigration rates are linear combinations of 
[Z(t)]m,m 
= E aid [ eo;t _ ef3;dt _ e<ok+ot)t _ ef3;dt] 
d=l 8j - 8k - 81 8j - f3id 8k + 81 - f3id ' 
where m = (i - l)n3 + (j - l)n2 + (k - l)n + l; 
[Y(t)]m,m 
For a subcritical process with immigration rates converging to constants 'f/ = [rJi, ... , 'T/r], 






respectively, permitting explicit evaluation of the equilibrium variance. 
Finally, with initial counts [n1, ... , nr] and immigration of all types of particles, the 
overall covariance matrix is given by 
r r 
Var(Zt) = l:niVi(t) + LWi(t). (3.26) 
i=l i=l 
3.5 Generating Functions for Multitype Branching Processes 
Recall Qi(t, s) is the probability generating function of Zt starting from Z0 = lLj. It 
is well-known that Qi satisfy the backward system of ordinary differential equations 
(3.27) 
with initial conditions Qi(O, s) = si. 
In the presence of immigration, we supplement (3.27) by the multivariate generating 
functions for the descendants of immigrating particles of type i, say Ri(t, s). Again 
first we assume that the process starts from no particles and only type i particles are 
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immigrating with rate 'T/i(t). Applying the Campbell's formula (3.11) for random vector 
sum Zt [see (3.16)], 
[4(t, s) - exp{ ft·"f:)sn-l)Pin(t-T)1Ji(T)dT} lo n 
= exp{ rt[E SnPin(t - 'T) - EPin(t - T)]rJi('T) dT} lo n n 
= exp{ht 1Ji(T)[Qi(t - T,s) -1] dT}. 
By independent evolution of clans and the product formula for generating functions (3.5), 
given non-constant immigration rates 'Tli(t) for 1 :Si :Sr, it follows that 
r t 
R(t, s) = IT !4(t, s) = e-'2:;=1fo 11.(r)[l-Q;(t-r,s)Jdr. (3.28) 
i=l 
When immigration rates are exponential, i'T/i(t) = aief3;t, we define functions 
which can be differentiated to produce 
(3.29) 
with initial condition Hi(O, s) = 0. 
Differential equations (3.29) can be numerically integrated simultaneously with the 
system (3.27) and the overall generating function is, via product formula (3.5), 
r 
Q&p(t, s) = R(t, s)Q(t, s)n = ( e- '2:;=1 Hi(t,s)) IT Qi(t, st;. (3.30) 
i=l 
When the immigration rates are linear combination of exponential functions, 1Ji(t) = 
f3·1t + /3·vt - .._.v f3·dt th H (t ) - .._.v H (t ) h ai1 e • ... aive ' - L...d=l aide • , en i , s - L...d=l id , s , w ere 
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3.6 Extinction Probability 
In the absence of immigration, Qi(t, 0) is the probability that the process is extinct 
by time t starting from Zo = ui. It is intuitively clear that Qi(t, 0) monotonically 
increases to a limiting value Xi· Setting the right-hand side of (3.27) equal to 0 and 
s = 0, the extinction probabilities x = [x1i ... , Xr] are given by the algebraic system 
x = P(x). Extinction is certain, x = 1, for both subcritical and critical processes. For a 
supercritical process, extinction is uncertain, and owing to irreducibility, all components 
xi of x satisfy Xi < 1. 
It is possible for extinction to occur in the presence of immigration if the rate of 
immigration falls sufficiently rapidly to zero [Dorman et al. (submitted)]. Lettings= 0 
and t ~ oo in Eq. (3.28) and assuming exponential immigration rates 1/i(t) = aief3tt with 
/3i < 0, we find that the ultimate extinction probability for the immigration system is 
Starting from initial counts Z0 = [n1, ... , nr], the independent behavior of initial and 
subsequent immigrant-founded clans yields an ultimate extinction probability of 
ability turns out to be 
Sometimes we are interested in the probability that no type j particles are present at 
time point t, i.e., e;(t) = Q17p(t, 1;), where Q17p(t, s) is the overall generating function for 
process {Zt} and 1; is the vector of ls except the jth entry 0. When immigration rates 
are exponential, we can calculate e; ( t) by numerically integrating the ordinary differen-
tial equations for Qi(t, s) (3.27) and Hi(t, s) (3.29) with s = 1; and initial conditions 
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Qi(O, lj) = 1 - li=j and Hi(O, lj) = 0. Then we evaluate Qbp(t, lj) by product for-
mula (3.30). Similarly, the probability that no particles are present at time point t, i.e., 
e(t) = Qbp(t, 0), can be obtained by settings = 0 and solving the ordinary differential 
equations (3.27) and (3.29) with initial conditions Qi(O, 0) = 0 and Hi(O, 0) = 0. 
3. 7 Marginal Distributions 
The marginal distribution of particle counts produced by any system governed by 
R(t, s), Qi(t, s), or product of these can be retrieved by Fourier transform [Henrici (1979), 
Lange (1982), Dorman et al. (submitted)]. In the current setting, if we seek the marginal 
distribution of the ith particle type, 1 ~ i ~ r, then we set all Sj = 1 except for si, 
which we vary over the boundary of the unit circle. 
I 
(i) Choose N sufficiently large that no Pk= Pr(Zti = k) with k ~ N is significant; 
(ii) Numerically integrate the differential equation Eq. (3.27) and Eq. (3.29) for the gen-
erating functions Qi(t, s) and Hi(t, s) and evaluate Eq. (3.30) for each boundary value 
(iii) Take finite Fourier transform to recover the coefficients of the marginal distribu-
tion. Practically, this finite Fourier transform can be evaluated by the fast Fourier 
transform [Press et al. (1992)]. 
Accuracy can be checked by comparing the numerically computed mean and variance 
with the theoretical mean and variance when these are available. The method works 
best if the marginal distribution is near 0, as is the case for most subcritical processes 
or subcritical processes renewed by moderate immigration. It fails for supercritical pro-
cesses if the time index tis sufficiently large for explosive growth to take hold. However, 
in these cases, the deterministic models may well suffice. 
If we want to seek the joint distribution of type i 1 and type i 2 particles, then we 
set all Sj = 1 except for sin si2 , which we vary over the complex unit ball. In this 
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case, the distribution can be approximated by appropriate two-dimensional finite Fourier 
transform. 
3.8 Total Descendants 
In a subcritical process, we may be interested in the ultimate number of particles Yi; 
of type j descendent from an ancestral particle of type i. The original particle is included 
when j = i. Let Yi = [Yi1, ... , Yir J and define matrix F with entries F ii = Iii = 8~. P;, ( 1), 
1 
matrix A with entries aii = E(Yi;) and covariance matrix Bi = Var(Yi), it can be 
shown [see Dorman et al. (submitted)], via first step analysis, that 
A=(l-F)-1 (3.31) 
and 
Vec(B) =(I - F)-1 ®(I - F*)-1 ®(I - F*)-1Vec(G), (3.32) 
where Vec(B) is the vectors Vec(Bi) stacked together and Vec(G) is the vectors Vec(Gi) 
stacked together. Recall that calculation of Gi is given by formula (3.4). 
Let Di(s) be the multivariate generating function of Yi = [Yi1, ... , l'ir] and D(s) = 
[D1(s), ... , Dr(s)]. Again by conditioning on the immediate descendants X of the orig-
inal type i ancestor, 
Di(s) = L Pr(Yi = n)s0 = L L Pr(Yi = nlX = m)Pr(X = m)s0 
= Su; L Pim L Sn-u;Pr(m1Y1 + · · · + mrYr = Il - \Ii) 
m2:0 n-u;2:0 
- SU; L PimD(s)m = siPi[D(s)]. (3.33) 
m2:0 
The distribution specified by Di can be retrieved by Lagrange's expansion [Good (1960), 
Harris (1963) pp.47]. 
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Sometimes we are interested in the total number of type j particles up to time 
point t, say li;(t), when the process starts with initial condition ui. Let Yi(t) = 
[li1(t), ... , lir(t)], Di(t, s) be the probability generating function of Yi(t) and D(t, s) = 
[D1(t, s, ... , Dr(t, s)]. A nearly identical system of ordinary differential equations as (3.27) 
can be derived. Conditioning on the lifetime of the ancestor type i particle, Ti, 
Di(t, s) - E(sY;(t)l'.li > t)Pr('.li > t) +lot E(sY;(t)l'.li = T)Pr('.li = T) dT 
= Sie-w;t + 1t[L Pin8n1Y1(t-r)+··+nrYr(t-r)+u;]wie-w;r dT 
O n2'.0 
= sie-w;t + siwi 1t[L PinD(t - T, s)°]e-w;r dT 
O n2'.0 
= Sie-w;t + SiWi lot Pi[D(t - T, s)]e-w;r dT. 
Multiplying this integral equation by ew;t, changing variable of integration from T to 
t - T and then differentiating with respect to t consequently produces 
(3.34) 
Relationship (3.33) can be retrieved by setting the left side of (3.34) to 0 and letting 
t-+ 00. 
The moments and marginal distributions ofYi(t) can be obtained by similar methods 
in previous sections. 
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CHAPTER 4. Production of Resistant Mutant Virus Before 
and During Antiviral Therapy 
4.1 Introduction 
Management of HIV infection has greatly improved in recent years since introduction 
of new treatment protocols called highly active antiretroviral therapy (HAART), that 
combine three or more highly potent drugs. AIDS has been transformed from a highly 
fatal disease into a chronic and somewhat manageable disease in developed countries 
where the antiretroviral medication is accessible [Pomerantz et al. (2003)]. However, 
treatment is not successful in all patients and may fail because of serious side effects, 
poor adherence to therapy, or emergence of resistant virus [Cohen (2002)]. 
To optimize treatment for a patient recently exposed to HIV, questions important 
to the clinical workers include: are there any drug resistant viral mutants present in the 
patient now, how many resistant mutants are there, and is it safe to prescribe potent 
monotherapy to which the wild-type virus is sensitive instead of expensive combination 
therapy which is inaccessible in some developing countries? Both phenotypic and geno-
typic assays have been proposed to test the existence of HIV drug-resistant isolates. 
However, due to the quasispecies nature of HIV, innumerable variants may exist in an 
infected individual and current methods are not sensitive enough to detect minor pop-
ulations such as drug resistant mutants [Shafer (2002)]. In view of these difficulties, 
mathematical models have been developed to investigate the generation of resistant vi-
ral mutants. Ribeiro et al. (1998) used a quasispecies equation of viral dynamics to 
31 
calculate the expected frequency of drug-resistant virus in untreated patients who are in 
the steady state. They calculated the equilibrium frequencies of resistant mutants that 
differ in one, two, three or more point mutations from wild-type virus and compared 
the effect of mutation and selection on the frequencies. However, their model was deter-
ministic and may not adequately account for the random fluctuation and extinction of 
small populations. In deterministic models, the frequencies of mutants are never zero. 
Only when the total body load of virus falls below one do the models predict "zero" 
mutants at equilibrium, though there may be substantial probability of extinction well 
before this point is reached. 
Another important issue concerning clinicians is to distinguish the source of resistant 
mutants that cause treatment failure. Two hypotheses were proposed to account for 
resistance related treatment failure [Ribeiro 'et al. (2000)]. The preexistence hypothesis 
says treatment fails when preexisting resistant strains are selected by the drug, while the 
emergence hypothesis holds that treatment failure is caused by resistant mutants that 
emerge de novo through residual virus replication during treatment. It is important to 
distinguish these two causes, because they require different counteractive strategies. A 
combination of drugs with a complex resistance profile is needed if the treatment failure 
is more likely to be caused by preexistence of resistant mutants, while minimizing any 
residual replication, e.g., by increasing dosage of drugs, will be the main objective if 
treatment is more likely to be caused by the resistant virus generated de novo during 
therapy. Based on a deterministic model, Ribeiro et al. {2000) compared the relative 
likelihoods of these two hypotheses by calculating the number of infected cells present 
at the start of therapy and the number of cells newly infected during therapy. They also 
translated their model into a stochastic one by substituting each deterministic rate with 
a probability and explored the model through simulation. Both models suggested that 
treatment failure is most likely caused by the preexistence of resistant mutants. 
In this chapter, we formulate stochastic branching process models to investigate the 
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emergence of drug-resistant mutants prior to and after treatment. As an illustrative 
example, a specific model is explored for the generation of viruses with mutations at 
three sites. This allows us to investigate the abundance of mutants with one to three 
resistance-related point mutations. The same model can be extended to an arbitrary 
number of mutations. The abundance of mutants at any time prior to treatment is 
characterized by means, variances, or numerically calculated marginal distributions. The 
probability of no mutants present during the initial bursting stage of the acute infection 
is also characterized. To determine the two possible causes for treatment failure, we 
calculate the mean and variance of the number of resistant mutants that are generated 
de novo during drug therapy and compare it to the abundance of resistant mutants in 
equilibrium prior to treatment. 
4.2 Formulation of the Branching Process Model 
Point mutation at one or two sites may be enough to confer resistance to a single drug. 
Resistance to combination therapy, however, requires several point mutations. Suppose 
mutations at n sites in the HIV genome are associated with resistance to a particular 
drug therapy. The fully resistant mutant is achieved by accumulation of mutations at all 
n sites. For each of the n relevant sites we consider one amino-acid substitution caused 
by a single base substitution. Mutations at different sites may be inherently different and 
occur at different rates, e.g., transitions are more likely to happen than transversions. 
Also the error rate of the reverse transcriptase may vary over different positions in the 
genome [Ricchetti et al. (1990), Klarmann et al. (1993)]. Therefore the mutation rates 
for then positions may be different. 
We define 2n subpopulations of productively infected CD4 T cells (PITs) according 
to the number and locations of the point mutations in the genome of the inhabitant 
HIV virus. There are (~) subpopulations of PITs infected by mutant with k mutations 
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where 0 ::::; k ::::; n. These subpopulations are connected by mutational events. Mutation 
at one of the n sites within the genome of wild-type virus produces single mutants. 
Further mutation at one of the remaining sites produces double mutants, and so on. 
The fully resistant n-mutant is achieved by accumulation of mutations at all n sites. 
The k-mutants can also be converted into (k - 1)-mutants by back-mutations. For 
simplicity, we exclude the possibility that two or more resistance-associated mutations 
occur simultaneously during one round of replication. Since productively infected T cells 
contribute most of the plasma virus particles found in patients [Klenerman et al. (1996), 
Bonhoeffer et al. (1997c)] and free virus dynamics are much faster compared with 
infected cell turnover [Perelson et al. (1996)], we do not consider a separate compartment 
of free virions, but simply assume that virion abundance is proportional to infected cell 
abundance. 
To understand the stochastic dynamics of the viral mutants during establishment 
of infection within the patient by drug-sensitive wild-type virus, we model the growth 
of PITs infected by wild-type virus deterministically and form a stochastic branching 
process model for the 2n - 1 subpopulations of PITs infected by HIV mutants. Mu-
tants are assumed to have impaired fitness compared to wild-type virus in the absence 
of drugs [Coffin (1995)]. We assume that, with competition from wild-type virus, the 
mutants cannot sustain growth in the absence of drug without renewal by mutation of 
wild-type virus, i.e., the mutants form a subcritical branching process. If some mutants 
have impaired fitness but are still able to establish infection in the absence of drugs, i.e., 
their growth is supercritical even with competition from wild-type virus, we can model 
these mutants deterministically and their frequencies relative to wild-type virus can be 
determined by the method in Ribeiro et al. (1998). Therefore the 2n -1 subpopulations 
of PITs constitute a subcritical multitype branching process and this process is con-
stantly refreshed by the immigration of mutants from the pool of wild-type virus. The 
reproduction rules governing the branching process, or more precisely the progeny gen-
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erating functions, can be set up according to available biological data. Since we exclude 
the possibility that mutations at two sites occur simultaneously during one round of 
replication, only single mutants can immigrate. Back-mutation from single mutants to 
wild-type is ignored as negligible. Although we can safely assume that the stream of new 
immigrants is Poisson, the intensity of immigration depends directly on the population 
size of the surrounding PITs infected by wild-type virus, which is subject to growth and 
decline. 
Figure 4.1 shows an illustrative example system with point mutations at three sites, 
a, b and c, associated with resistance to a specific drug therapy. We define 23 = 8 
subpopulations of PITs. P IT0 is the subpopulation of the PITs infected by the wild-
type virus; P ITa, P !Tb, and P !Tc by single mutants with one mutation at site a, b or c 
respectively; P !Tab, PIT be and PIT ac by the double mutant virus with two mutations 
at a/b, b/c or a/c respectively; PITabc by the triple mutant with mutations at all three 
sites a/b/c. For notational ease, these subpopulations are labeled 0 to 7 as in the 
figure. Growth of P IT0 is deterministic and the counts of PITs infected by mutants, 
{Zt = [Zn, ... , Zt7], t ~ O}, constitute a subcritical branching process with seven types 
of particles, where Zti is the count of type i particle at time point t. Here time 0 is the 
start of infection. The mutation events connecting these subpopulations are illustrated 
by arrows in the figure. Mutation rates at sites a, band care ma, mb and me per base 
per replication cycle respectively. 
The growth of the mutant subpopulations is determined by the effective reproductive 
numbers [Anderson et al. (1991)], ~' 1 $ i $ 7. In this chapter, ~ is defined as the 
average number of secondary infected cells produced by a type i infected cell under the 
given conditions. ~ reflects the replicative capacity (fitness) of the inhabitant virus 
within the type i cells and is also a function of the environment, e.g., abundance of sus-
ceptible cells and host immunity. By assumption, mutant viruses are expected to have 
an effective reproductive number less than 1 in the presence of wild-type virus without 
. ,, 
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Figure 4.1 A schematic illustration of the system with three point mu-
tations between sensitive wild-type virus and resistant mutant 
virus. 
treatment. Let C be the clearance rate of productively infected T cells, which can be 
determined from the half life of productively infected cells upon usage of potent an-
tiretroviral drugs [Section 2.4]. Note host cells may be killed by both immune-mediated 
cellular destruction and cytopathic effects of virus. Productively infected T cells infected 
by different viral variants may experience different death rates, Ci· However, due to the 
lack of biological data to differentiate these values, we assume Ci = C in the following. 
In addition, we suppose that the population of viral mutants remains small relative to 
the whole virus population and host immunity is approximately constant during the rise 
of resistant mutants, so the values of Ris and C do not change with time. In other 
words, the process is time homogeneous. 
Let µi, 1 :::; i :::; 7, be the death rate of type i PITs and Aij denote the rate at 
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which type i PITs give birth to type j PITs. Table 4.1 summarizes the translation of 
biologically meaningful quantities into birth and death rates for each type of PITs. 
Table 4.1 Relationship between biological meaningful quantities and birth 
and death rates for each particle. 
µi c µ2 c 
..\14 mbCR1 ..\24 maCR2 
..\1s mcCR1 ..\26 mcCR2 
..Xu (1- mb - mc)CR1 ..\22 (1- ma - mc)CR2 
µ3 c µ4 c 
..\35 maCR3 ..\41 mbCR4 
..\35 mbCR3 ..\42 maCR4 
..\33 (1 - ma - mb)CR3 ..\41 mcCR4 
..\44 (1- ma - ffib - mc)CR4 
µs c µ6 c 
..\s1 mcCRs ..\52 mcC~ 
..\53 maCRs ..\53 mbC~ 
..\s1 mbCRs ..\51 maC~ 





..\77 (1- ma - mb - mc)CR1 
To translate the birth and death process into a branching process, we use the pro-
cedure outlined in Section 3.2. In the corresponding multitype branching process, type 
i particles have an exponentially distributed life time with rate Wi = µi + 2:J=1 Aij = 
C(l + ~). According to formula (3.3), the progeny generating function for type 1 
particles is 
Similarly, we obtain progeny generating functions for particles of other types as 
37 
Pa(s) 1 Ras a - 1 +Ra + 1 +Ra [mass + mbs6 + (1 - ma - mb)sa], 
1 R4s4 
- l + ~ + l + R4 [mbs1 + mas2 + mcs1 + (1 - ma - mb - mc)s4), 
Ps(s) 1 Rsss - 1 +Rs + 1 +Rs [mcs1 + masa + mbs1 + (1 - ma - mb - mc)ss], 
1 ~s6 
- l + ~ + l + ~ [mcs2 + mbsa + mas1 + (1 - ma - mb - mc)s6], 
1 R1s1 
- 1 +R1 + 1 + R7 [mcs4 +mbss + mas6 + (1- ma - fib - mc)s7]. 
Study of the process {Zt} is through a set of probability generating functions, Qi(t, s), 
1 $ i $ 7, that are defined by formula (3.2) and satisfy the system of backward differ-
ential equations (3.27). 
Calculating !:- · = -1L P.-( 1) and n · · IJ 8s; I IJ = Wi (jij - li=j), we get the f! matrix of the 
branching process 
0 0 mbR1 mcR1 0 0 
0 0 maR2 0 mcR2 0 
0 0 0 ma Ra mbRa 0 
f!=Cx fib~ ma~ 0 0 0 mcR4 
me Rs 0 ma Rs 0 0 mbRs 
0 me~ mb~ 0 0 ma~ 
0 0 0 mcR1 mbR1 maR1 
where the diagonal entry at row i is set such that row i of n sums to C ( Ri - 1). 
Exact expressions for the eigenvalues of n are complicated. However, if we ignore 
back-mutations, then n reduces to an upper triangular matrix whose eigenvalues are 
exactly the diagonal entries. When~ < 1 for 1 $ i $ 7, all eigenvalues are less than 
zero and we can see that the mutants constitute a subcritical branching process. 
With progeny generating functions in hand, we now consider immigration. Since 
we exclude the possibility that mutations at two sites occur simultaneously during one 
round of replication, we assume that only single mutants, P !Ta, P In, and P !Tc, are 
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immigrating according to independent Poisson processes. The intensity of immigration 
depends directly on the abundance of the surrounding P IT0 , which is subject to growth 
and decline. We characterize the growth of P IT0 according to the clinical course of HIV 
infection [Daar et al. (1991), Clark et al. (1991), Henrard et al. (1995), Schacker et 
al. (1998)]. 
The acute phase of HIV infection lasts only a few weeks, with blood viral load and 
infected CD4 T cell count increasing dramatically and then declining by two or more 
orders of magnitude to a stable equilibrium. The decline of viral load and infected CD4 
T cell count may involve target-cell limits, immune response or both. Acute symptoms 
occur in patients during the acute phase. Then after about 10 years of clinical latent 
phase, -the CD4 T cells of the body are depleted ( < 200 cells per µl) and AIDS develops. 
This pattern is also observed in a basic population model for HIV primary infec-
tion [Nowak et al. (1996), Bonhoeffer et al. (1997c)], reviewed in Chapter 2, Section 
2.4. By numerically solving the nonlinear differential equations (2.4), the basic model 
shows a dramatic growth phase of virus and infected cells followed by decline to an 
equilibrium. The solid line in Figure 4.2 shows the dynamics of infected cells during 
primary infection using typical parameter settings. This pattern jibes with the clinical 
course of HIV infection and the animal model established by infecting rhesus macaque 
monkeys by simian immunodeficiency virus (SIV) [Nowak et al. (1997b)]. Interestingly, 
the model does not require a specific immune response to control virus after the initial 
expansion. 
For mathematical convenience, we divide the growth of P IT0 into two stages and 
approximate by exponential functions. Let n0 be the initial inoculum of P IT0 , npeak the 
peak load of P IT0 , neq the P IT0 load at equilibrium and T peak the time P !To reaches 
npeak. In the early acute stage, the population of P !To explodes exponentially from n0 
to npeak with rate f31 = (lognpeak-Iogno)/Tpeak· In the late acute and chronic stage, the 
population declines from npeak to neq exponentially according to (npeak - neq)ef3ut + neq, 
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where {311 is negative and can be set by clinical data or fitting to the solution to the basic 
model. As comparison, the approximation is shown as a dashed line in Figure 4.2. With 
immigration rates being exponential or linear combinations of exponential functions, the 
mean and variance of Zt can be calculated analytically by formulas (3.19) and (3.26) 
respectively. The probability generating functions Qi(t, s) for particle i and R(t, s) for 
immigrants combine as in equation (3.30) to give the overall probability generating 
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Figure 4.2 Dynamics of P IT0 during primary infection calculated by the 
basic model (solid line) and approximation by exponential 
functions (dashed line). Parameter setting [see Section 2.4): 
,\ = 5 x 107,d = 0.1,a = 0.7,/3 = 5 x 10-10,k = 100,u = 5. 
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4.3 Results 
4.3.1 Early Acute Stage 
As a numerical illustration, we take typical parameter values, listed in Table 4.2, and 
investigate the dynamics that generate viral mutants during the early acute stage. The 
means and variances of different mutants during this stage are calculated and marginal 
distributions obtained by numerical methods. We also examine the probability ei(t) that 
no type i mutants are present and the probability e(t) that no mutants of any type are 
present in the body at time point t during the early acute stage. Then the sensitivity 
of the dynamics to uncertainty in the parameters is explored. 
An illustrative example using typical parameter settings 
In this example, we assume that the mutation rates at all three sites are the same, 
i.e., ma = mb = me = 3 x 10-5 per base per replication cycle, and the fitness of 
mutants decreases with the number of point mutations, e.g., R1 = R2 = R3 = 0.95, 
R4 = Rs = ~ = 0.90 and R1 = 0.85. 
Table 4.2 Typical parameter settings. 
Parameters Notation 
Cell clearance rate c 
Mutation rates ma, mb, me 
Reproductive numbers R1, R2, Ra 
Reproductive numbers ~,Rs, Re 
Reproductive number R1 
Initial inoculum of P !To no 
Peak load of P !To rlpeak 
Equilibrium load of P !To neq 
Time to reach npeak Tpeak 
Decay rate in chronic stage /311 
Value 
0.7 





5 x 108 




/day Markowitz et aL (2003) 




Haase ( 1999) 
First we consider the immigration rates of single mutants during the early acute stage. 
Suppose the infection starts with an inoculum of n0 = 10 P ITos and reaches peak load, 
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npeak = 5 x 108 , Tpeak = 10 days after infection. Then /31 = [log(5 x 108 ) - log 10]/10 = 
1. 7728. At time t, there are n0ef31t P IT0s, so the rate of immigration for particle 1 (P !Ta) 
is 171 ( t) = maR.oCn0ef31t, where ma is the mutation rate at site a and R.o is the average 
number of secondary PITs produced from a P IT0 particle. Note the constants (31 and 
R.o are related by the identity /31 = (R.o - l)C since reproduction must be adjusted for 
death to compute the net rate of exponential growth. Thus 171(t) = ma(/31 + C)noef31t. 
Calculation of immigration intensity for particles 2 (P In) and 3 (P !Tc) is similar. 
Employing formulas (3.18) and (3.26), we are able to calculate analytically the mean, 
E( Zt), and variance, Var( Zt), of the counts of particles 1-7 in the presence of immigration 
of single mutants from the pool P IT0 [Figure 4.3]. The mean numbers of single mutants 
(particles 1,2,3), double mutants (particles 4,5,6) and the triple mutant (particle 7) are 
plotted against time as solid lines. The mean plus/minus the standard deviation (SD) is 
plotted as dotted lines. The deterministic growth of P IT0 is also plotted as comparison. 
Numerical values at days 0, 2, 4, 6, 8, 10 are listed in Table 4.3. 
Table 4.3 Mean±SD and e;(t) of mutants on days 0, 2, 4, 6, 8, 10 in the early acute stage 
using parameter values in Table 4.2. 
Time Single mutants 
0 0.0000 ± 0.0000(1.0000) 
2 0.0138 ± 0.1512(0.9892) 
4 0.4925 ± 0.9199(0.6830) 
6 17.0815 ± 5.4229(0.0000) 
8 592.0100 ± 31.9261(0.0000) 
10 20517.4456 ± 187.9507(0.0000) 
Double mutants Triple mutant 
0.0000 ± 0.0000(1.0000) 0.0000 ± 0.0000(1.0000) 
0.0000 ± 0.0007(1.0000) 0.0000 ± 0.0000(1.0000) 
0.0000 ± 0.0049(1.0000) 0.0000 ± 0.0000(1.0000) 
0.0004 ± 0.0292(0.9997) 0.0000 ± 0.0002(1.0000) 
0.0128 ± 0.1719(0.9900) 0.0000 ± 0.0010(1.0000) 





























































































































































































































As we can see from the mean numbers, during this bursting stage, single mutants rise 
to the order of 104 in concert with the exponential growth of P IT0 , while the presence of 
double and triple mutants remains uncertain. Inference based on the mean and variance 
may be biased if the distribution is skewed, as is clearly the case for double and triple 
mutants. To get a clearer picture, we also utilized the numerical methods, reviewed in 
Chapter 3, section 3.7, to obtain the marginal distributions of mutants at various time. 
Distributions of single mutants at days 6, 8 and of double and triple mutants at days 
6, 8, and 10 are shown in Figure 4.4. Note the marginal distributions are obtained by 
numerical methods instead of exact calculation. Comparing the numerical mean and 
standard deviation calculated from the marginal distribution, displayed in Figure 4.4, 
with the analytical ones in Table 4.3 can reveal the precision of numerical approximation. 





















































































































































































































































































































The distributions of single mutants ( P !Ta, P 1n and P !Tc) are skewed when particle 
counts are low. As particle numbers increase with time, the distribution becomes more 
symmetric and similar to a normal distribution. By day 6, a few to a few dozen single 
mutants are already present in > 99% of the patients. The presence of double mutants 
remains a matter of chance during this stage. On day 6, the distribution of double-
mutants (PITab, PITac or PITbc) is well concentrated on 0. However on the 8th day, 
each double mutant is expected in about 1 % of patients and by day 10 this percentage 
has increased to 29%. Throughout the early acute stage, the distribution of triple mutant 
is concentrated on 0. 
To answer the question whether a specific mutant is present at time t, the probability 
that no type i particle is present at time t, ei(t) = Pr(Zti = 0) = Qbp(t, li), where li is 
the vector with all entries 1 except the ith entry 0, can be retrieved from the marginal 
distribution of particle i at time t or direct numerical integration of the differential 
equations (3.27) and (3.29) for probability generating functions Qi(t, s) and Hi(t, s) 
evaluated at s = li with corresponding initial conditions [see Section 3.7]. The ei(t) 
for i = 1, 4, 7 are plotted in Figure 4.5 and numerical values for i = 1, 4, 7 and t = 
0, 2, 4, 6, 8, 10 are recorded in Table 4.3. It is clear from Figure 4.5 that single mutants 
are appearing fast. They will be present in more than 90% of patients only ""5 days 
after infection. The appearance of mutants is delayed as number of point mutations 
increases. If we take 0.95 as a cut-off, double mutants appear about 6 days after single 
mutants. 
To know the time period in early infection during which it is safe to administer 
monotherapy instead of combination therapy, we consider the "extinction probability" 
that there are no mutants of any type at time t, say e(t). Intuitively, due to the ex-
ponential growth of the immigration rate, e(t) = Qbp(t, 0) will decrease monotonically. 
By setting s = 0, numerically integrating the backward system of ordinary differential 
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Figure 4.5 The probability of no type i particle, ei(t), for single (i = 1), 
double (i = 4) and triple (i = 7) mutants during the early acute 
stage using parameter values in Table 4.2. 
responding initial conditions and product formula (3.30), we calculate and plot the e(t) 
during the early acute stage in Figure 4.6. We observe that the "extinction probability" 
declines rapidly from 0.95 to 0.05 during days 2.3-4.5. If we set 0.05 as a cut-off, only 
the treatments initiated in the first 2.3 days after infection will catch more than 95% 
of patients before any resistance mutants have appeared. But after 4.5 days, mutants 
are present in more than 95% of patients and caution must be taken when instituting 
treatment, especially monotherapy. 
With these parameter values, the model has some practical implications for treatment 
started in the early acute stage. If resistance requires three or more point mutations, 
resistant mutants have virtually zero probability of appearing during the early acute 
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Figure 4.6 "Extinction probability" e(t) during the early acute stage. 
the dosage) is an effective way to strangle the virus. If resistance requires two point 
mutations, nearly 30% of patients will have a few resistant mutants by day 10. When 
resistance requires only one point mutation, the early high abundance of single mu-
tants will cause rapid selection of resistant virus and lead to therapy failure. Thus the 
resistance profile of drug therapy should be considered even very early in disease. 
Sensitivity of the dynamics to parameter settings 
So far, we have explored the dynamics for generation of mutants in the early acute 
stage using the typical parameter settings in Table 4.2. It would be instructive to see 
the sensitivity of the dynamics to different parameter settings. The growth of wild-type 
P IT0 and mutant fitness are not expected to be the same in different patients because 
of inter-individual variability, while mutation rates are not expected to be the same for 
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different sites and viruses. We vary the values of different parameters and report the 
mean±SD of mutants at end of the early acute stage and the "extinction windows" 
during which e(t) declines from 0.95 to 0.05. Trajectories of means and the "extinction 
probability" e(t) under different parameter values are collected and plotted in Appendix 
for reference. An "upper bound" of how many mutants may be generated during the 
early acute stage is also obtained by setting the parameters to be extremely favorable 
for generation of mutants. 
Different patients may start with different inoculum sizes n0 of P IT0 at the start of 
infection and reach different peak loads npeak of PIT0 at different times Tpeak· With other 
parameters in Table 4.2 fixed, we vary the starting inoculum n0 of P IT0 and record the 
mean±SDs at day 10 and the extinction windows with starting inoculum n0 =l, 10, 100, 
500, and 1000 in Table 4.4. Similarly, fixing n0 = 10 and T peak = 10, we vary values of 
npeak and record the outcome for npeak = 0.1, 0.5, 1, 5, 10 x 108 in Table 4.5. According to 
the simulation of stochastic models by Tuckwell et al. (1998) and Kamina et al. (2001), 
the time Tpeak to reach peak load npeak, ranges from 19 days to 27 days. Experimental 
observation of SIV infection dynamics in pigtail macaques shows T peak to be 10 to 21 
days. Fixing no = 10 and npeak = 5 x 108 , results for T peak = 5, 10, 15, 20, 25, 30 are given 
in Table 4.6. 
As shown in Table 4.4 and Table 4.5, the starting inoculum has relatively small 
influence on the mean counts of mutants, but the curves of "extinction probability" e(t) 
are shifted significantly by various starting inoculum. For instance, with n0 = 1000, the 
e(t) falls from 0.95 to 0.05 during days 0.3 to 2.6, which is quite different from n0 = 10 
(days 2.3 to 4.5). This indicates that the larger starting inoculum a patient receives, the 
more quickly mutants are appearing. On the contrary, the peak load npeak of P IT0 has 
greater influence on the count of mutants than on the e(t). The larger the peak load, 
the more mutants are generated during the early acute stage. The same no and npeak 
but different T peak should stretch the process in time, as evidenced in the trajectories 
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of mean and "extinction probability" e(t) [Figure A.3 in Appendix). With larger Tpeak, 
more mutants accumulate at end of the early acute stage [Table 4.6]. 
Table 4.4 Mean±SD of mutants on day T peak = 10 and the ''windows" during which e( t) 
declines from 0.95 to 0.05 with no = 1, 10, 100, 500, 1000. Other parameters 
are set as in Table 4.2. 
no Single mutants Double mutants Triple mutant Window( days) 
1 19894.0864 ± 180. 7137 0.3829 ± 0.9107 0.0000 ± 0.0051 3.1-5.1 
10 20517.4456±187.9507 0.4442 ± 1.0119 0.0000 ± 0.0061 2.3-4.5 
100 21322.7747 ± 197.2548 0.5276 ± 1.1443 0.0000 ± 0.0073 1.2-3.7 
500 22041.1148 ± 205.5134 0.6058 ± 1.2639 0.0000 ± 0.0085 0.5-2.9 
1000 22403.3511 ± 209.6640 0.6467 ± 1.3247 0.0000 ± 0.0091 0.3-2.6 
Table 4.5 Mean±SD of mutants on day Tpeak = 10 and the ''windows" during which e(t) 
declines from 0.95 to 0.05 with npeak = 0.1,0.5, 1, 5, lOx 108 . Other parameters 
are set as in Table 4.2. 
npeak( x 108 ) Single mutants Double mutants Triple mutant Window( days) 
0.1 440.8223 ± 29.0640 0.0121 ± 0.1787 0.0000 ± 0.0012 2.9-5.8 
0.5 2132.2775 ± 62.3775 0.0528 ± 0.3619 0.0000 ± 0.0023 2.6-5.2 
1 4211.3310 ± 86.8425 0.0999 ± 0.4921 0.0000 ± 0.0031 2.5-4.9 
5 20517.4456±187.9507 0.4442 ± 1.0119 0.0000 ± 0.0061 2.3-4.5 
10 40627.4134 ± 262.4623 0.8478 ± 1.3842 0.0000 ± 0.0081 2.2-4.3 
Large mutation rates will accelerate the generation of mutants. With the parameters 
other than mutation rates set as in Table 4.2, the mean±SD of mutants at day T peak = 10 
and extinction windows with ma = mb = me = 3 x 10-5 [Mansky et al. (1995)) 
and ma = mb = me = 4 x 10-5 [Mansky et al. (1996)] are recorded in Table 4.7. 
With the larger mutation rates, the mean number of single mutants at the end of the 
early acute stage increases by thousands and the curve of "extinction probability" shifts 
forward in time by hours. In addition, different mutation rates at different sites will 
favor some mutants more than others, as shown in Table 4.8, where ma = 4 x 10-5 and 
mb = me = 3 x 10-5 . In this setting, a higher mutation rate at site a promotes the 
single mutant P ITa and as a consequence, the double mutants PIT ab, P !Tac and triple 
mutant P ITabc. 
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Table 4.6 Mean±SD of mutants on Tpeak and the ''windows" during which e(t) declines 
from 0.95 to 0.05 with Tpeak = 5, 10, 15, 20, 25, 30. Other parameters are set 
as in Table 4.2. 
Tpeak(day) Single mutants Double mutants Triple mutant Window( days) 
5 17785. 7200 ± 155.9753 0.1963 ± 0.5743 0.0000 ± 0.0024 1.2-2.2 
10 20517.4456± 187.9507 0.4442 ± 1.0119 0.0000 ± 0.0061 2.3-4.5 
15 23196. 7312 ± 218. 7258 0. 7392 ± 1.4593 0.0000 ± 0.0106 3.4-6.7 
20 25825.0725 ± 248.4701 1.0773 ± 1.9172 0.0001 ± 0.0158 4.5-9.0 
25 28403.9088 ± 277.2891 1.4545 ± 2.3829 0.0001 ± 0.0215 5.5-11.2 
30 30934.6257 ± 305.2568 1.867 4 ± 2.8537 0.0002 ± 0.0277 6.6-13.3 
Table 4.7 Mean±SD of mutants on day Tpeak = 10 and the ''windows" during which e(t) 
declines from 0.95 to 0.05 with m = ma = mb = me = 3 and 4 x 10-5 • Other 
parameters are set as in Table 4.2. 
m 
3 x 10-5 
4 x 10-5 
Single mutants Double mutants 
20517.4456 ± 187.9507 0.4442 ± 1.0119 
27356.3929 ± 217 .0256 0. 7897 ± 1.3493 
Triple mutant 
0.0000 ± 0.0061 




The fitness profile of mutants is an important determinant of the process. In the 
former examples, we assumed that the mutants have sequentially decreasing fitness with 
the number of point mutations. However, the fitness profile of mutants may be quite 
variable, sometimes as a function of the environment. For example, the fitness of the 
intermediate mutants (single and double mutants) may effect the generation of triple 
mutants. In Table 4.9, we record mean±SD of different mutants at day T peak = 10 for 
three fitness profiles. 
The first row is the previously considered case where mutants have sequentially de-
creasing fitness. The second row emulates the scenario when all intermediate mutants 
have high fitness. On day 10, there are an average 20840 ± 192 single mutants present. 
Table 4.8 Mean±SD of mutants on day T peak = 10 when ma = 4 x 10-5 and 
mb = me = 3 x 10-5 . Other parameters are set as in Table 4.2. 
27356.5942 ± 217.0268 20517.3702 ± 187.9502 0.5923 ± 1.1685 0.4442 ± 1.0119 0.0000 ± 0.0070 
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Table 4.9 Mean±SD of mutants at day 10 under different fitness profiles of intermediate 
mutants. Here R1 = R2 = R3 = Rs and R4 = R5 = Rt; = Rd and R1 = 0.85. 
Other parameters are set as in Table 4.2. 
Rs Rd Single Mutants Double Mutants Triple Mutants Window( days) 
0.95 0.90 20517.4456 ± 187.9507 0.4442 ± 1.0119 0.0000 ± 0.0061 2.3-4.5 
0.99 0.99 20840.2097 ± 192.3688 0.4869 ± 1.1139 0.0001 ± 0.0067 2.3-4.5 
0.50 0.50 17473.0301±149.7309 0.1729 ± 0.5136 0.0000 ± 0.0027 2.3-4.5 
We also compute the marginal distributions of double and triple mutants at day 10 [see 
Figure A.6 in Appendix]. There is about 31 % chance for each type of double mutant 
(PIT ab, PIT ac or PIT be) to be present at day 10, slightly different from the case in first 
row (0.2949). The chance to have any triple mutant PIT abc present is near 0. In the third 
row, all intermediate mutants have low fitness and thus cause a barrier for generation 
of the triple mutants. The average number of single mutant at day 10 drops to 17 4 73. 
I 
Now there is only a chance of 14% of having one or more of each double mutant present 
by day 10. The chance to have any triple mutant present is still near 0 [Figure A. 7]. 
The three profiles in Table 4.9 have little effect on the time evolution of the "extinction 
probability" e(t) [Figure A.8]. 
So far we have explored the sensitivity of results to a specific parameter by varying 
its value while other parameters remain fixed. To get an "upper bound" of how many 
mutants can be generated during the early acute stage, we consider an extreme situation 
favorable for generation of mutants. The average number of each single mutant that 
immigrates during the early acute stage should be the area under the growth curve of 
its immigration rate 
{Tpeak mno(/h + C)ef31t dt = mno(/31 + C) (ef31Tpeak - 1) 
lo /31 
( CTveak )( ) m1+ 1 1 npeak-no· og npeak - og no 
( 4.1) 
To maximize the number of immigrants while retaining biologically reasonable values 
for the parameters, we set no = 1000, npeak = 10 x 108, Tpeak = 30, ma = mb = me = 
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4 x 105 , ~ = 0.99, 1 $ i $ 7. Mean±SDs of mutants at day Tpeak = 30 are shown in 
Table 4.10 and the trajectory of means in Figure 4.7. Now the mean number of any 
single mutant at the end of the early acute stage is near 105 and double mutants near a 
dozen. The mean number of triple mutant is still around 0. As shown in Figure 4.8, the 
"extinction probability" e(t) declines from 0.95 to 0.05 during days 0.4 - 6.4. Marginal 
distributions of double and triple mutants at day 30 are also obtained [Figure 4.9]. Under 
this setting, on the order of 1 to 10 double mutants may be present with probability 
0.9978 at the end of the early acute stage, but the chance that triple mutants has been 
generated is still low, around 0.0011. 
Table 4.10 Mean±SD of mutants at day 30 with n0 - 1000, 
npeak = 10 x 108 , Tpeak = 30, ma = mb = me = 4 x 105 , and 
~ = 0.99, 1 :::; i :::; 7. 
Single mutants Double mutants Triple mutant 
99280.1072 ± 623.8806 11.7708 ± 8.9449 0.0021±0.1420 
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Figure 4.8 Time evolution of the "extinction probability" for n 0 = 1000, 
npeak = 10 x 108 , Tpeak = 30, ma = mb = me = 4 x 105, and 
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Figure 4.9 Marginal distributions of double mutants (upper graph) and 
triple mutant (lower graph) at day 30 for n0 1000, 
npeak = 10 x 108 , Tpeak = 30, ma = mb = me = 4 x 105 , and 
Ri = 0.99, 1 ~ i ~ 7. Other parameters are as in Table 4.2. 
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4.3.2 Late Acute and Chronic Stage 
Due to a decrease in the number of susceptible, uninfected CD4 T cells and/ or 
induction of host immunity, the number of P IT0 will decline and then stabilize as shown 
from clinical and experimental observations. If drug therapy is initiated after the early 
acute stage, knowledge of the dynamics that generate mutants in the late acute and 
chronic stage will be essential in guidance of treatment. 
From exploration of the dynamics in the early acute stage, it is clear that at the 
start of the late acute and chronic stage, the single mutants ( P !Ta, P In and P !Tc) are 
well represented on the order of 102 - 104• A few or a few dozen double mutants may 
be present depending on conditions. Triple mutants have near 0 probability to appear 
during the early acute stage. For sake of simplicity, we assume that during the late acute 
I 
and chronic stage the number of PIT0 , say n(t), declines from the peak load npeak to 
equilibrium load neq according to n(t) = (npeak-ne9)elhrt+neq, where {311 < 0 and can be 
determined from clinical observations, experiments in animal models, or by fitting to the 
solution of the basic dynamic model for primary infection. We set t = 0 at T peak and t > 0 
is the time since Tpeak· In this context, the counts of mutants {Zt = (Zn, ... , Zt7], t 2:'; 
O} still constitute a subcritical multitype branching process, with the single mutants 
immigrating from the P !To pool with rates m(/311 + C) ( npeak - neq )efh rt + mneqC. Here, 
mis equal to ma, mb or me for single mutants P !Ta, P !Tb or P !Tc· Note the immigration 
rates are linear combinations of exponential functions and converge to constants mane9C, 
mbneqC and mcne9C as t --+ oo. 
For this subcritical process with immigration rates converging to constants, a stochas-
tic equilibrium will be achieved between immigration (mutation) and extinction (selec-
tion). Let 
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be the vector of equilibrium immigration rates and 
m(t) = [m1(t), ... , mr(t)] 
be the vector of expected particle counts at time t. The forward equations for means 
can be expressed in vector-matrix form as 
d 
dt m(t) = m(t)n + 71(t). 
Setting this equation to 0 and solving, we obtain the mean at equilibrium as 
which jibes with formula (3.20). The exact solution of this linear system is complicated 
to write down. But if we neglect back-mutations, we obtain an elegant approximation 
maneq maneq 
- 1 - (1 - mb - mc)R1 ~ 1 - Ri; 
mbneq ,....., mbneq . 
1 - (1 - ma - mc)R2 ,..., 1 - R2' 
m3 -
mcneq mcneq 
1 - (1 - mb - mc)R3 ~ 1 - R3; 
m4 = mambneq ( Ri + R2 ) ~ mambneq ( Ri R2 ) 1- (1- ma - mb - mc)R4 1- Ri 1- R2 1- R4 1 - Ri + 1- R2 ; 
m5 = mamcneq ( Ri + R3 ) ~ mamcneq ( Ri + R3 )· 1 - (1 - ma - mb - mc)R5 1 - Ri 1 - R3 1 - R5 1 - Ri 1 - R3 ' 
m6 = mbmcneq ( R2 + R3 ) l:::;j mbmcneq ( R2 R3 ) 1- (1- ma - mb - me)~ 1- R3 1- R3 1-~ 1- R3 + 1- R3 ; 
m4mcR4 + m5mbR5 + m6ma~ 
m1 = 1- (1 - ma - mb - mc)R1 
l:::;j 
mambmcneq [ R4 ( Ri + R2 ) 
1 - R1 1 - R4 1 - Ri 1 - R2 
+ R5 ( Ri + R3 ) + ~ R2 R3 
1 - Rs 1 - Ri 1 - R3 1 - ~ ( 1 - R2 + 1 - R3 )], 
where further approximation ( l:::;j) is made when mutation rates are much less than 1. 
This approximate solution has a clear interpretation. The average number of single 
mutants at equilibrium is proportional to the mutation rate at the associated site and 
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the equilibrium levels of wild-type infected cells neq and is inversely related to 1 minus 
its effective reproductive number, which can be considered a measure of the selection 
force. The frequency of double mutants is proportional to the mutation rates at the two 
associated sites and related to the effective reproductive numbers of the double mutant 
and its two predecessor single mutants. The abundance of triple mutant depends on 
mutation rates at all three sites and effective reproductive numbers of itself and all 
intermediate mutants. Formulas for variance/covariance of these counts at equilibrium 
can also be obtained through limits (3.25) but are too complicated to write down here. 
We are interested in the expected frequency of triple mutant relative to wild type 
virus at equilibrium m1/neq, a quantity that determines whether resistance testing can 
detect the mutant. We calculate the relative frequency under different combinations 
of effective reproductive numbers of single mutants, Rs = R1 = R2 = R3 , and double 
mutants, lltJ. = ~ = R5 =~[Figure 4.10]. Here we assume ma= mb =me= 3 x 10-5 
and R7 = 0.85. Variability in these two values will only shift the surface upward or 
downward. Not surprisingly, low values of both Rs and lltJ. block the generation of the 
triple mutant and the relative frequency is near O; only high values of both Rs and lltI. 
allow relatively high relative frequencies of triple mutant. When Rs = ~ = R1 ~ 1, the 
relative frequency reaches 0.037, but even this is not easily detectable. 
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Relative frequency of triple mutant at equilibrium 
0 0 




Figure 4.10 Relative frequency of triple mutant at equilibrium and its de-
pendence on the effective reproductive numbers of single mu-
tants and double mutants. Lower graph is the contour plot 
of the relative frequency. The contour elevation levels are 
1 x 10-14 , 10-13 , 10-12 , 10-11 , 10-10 and 10-9 from lower left to 
upper right. 
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Calculation of the mean and variance of the equilibrium counts is readily expanded 
to mutants that differ from wild-type virus by arbitrary n point mutations. Elegant 
approximation is obtained if we neglect back-mutation, assume all mutants have the 
same effective reproductive number R;, = R, 1 :'.S i ::::; n, and all sites have the same 
mutation rate m « 1 [Table 4.11]. 
Table 4.11 Mean and variance of mutants at equilibrium. 
Mutant with Mean Variance 
k-point mutations 
0 neq 0 
1 mne9 ~ 1-R (1-R) 
2 2m2 ne9 R 2m2 ne9 R (1-R)2 (1-R)3 
k k!neq ( mR )k R 1-R ~(mR)k R(l-R) 1-R 
n-2 (n-2)!ne9 ( mR ) n-2 (n-2)!ne9 ( mR) n-2 R 1-R R(l-R) 1-R 
n-1 (n-l)!ne9 ( mR) n-l (n-l)!neq ( mR) n-l R 1-R R(l-R) 1-R 
n n!neq ( mR)n n!ne9 ( mR)n R 1-R R{l-R) 1-R 
As a numerical example, we set the parameter values as in Table 4.2. The mean±SDs 
of mutants at equilibrium are tabulated in Table 4.12. Note, the means, variances, and 
distributions of particles at equilibrium are the result of interaction between mutation 
(immigration) and selection (fitness) and unrelated to the starting conditions. 
Table 4.12 Mean±SD of mutants at equilibrium. Parameters are set as in 
Table 4.2. 
Single mutants Double mutants Triple mutant 
23972.6859 ± 692.1636 13.6534 ± 14.7802 0.0074 ± 0.2945 
Taking the means at day 10 from the early acute stage (Table 4.3) as starting counts 
of mutants, the time evolution of mean±SDs of mutants in the late acute and chronic 
stage are plotted in Figure 4.11. The deterministic growth of P IT0 is also plotted 
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as comparison. We stress that the calculation is conditional on the specific starting 
conditions in Table 4.3. Variability in particle counts at the start of the late acute and 
chronic stage is overlooked for mathematical convenience. However we can observe that 
the means and variances converge to the equilibrium values, which do not depend on 


















































































































































































































































The distributions of double and triple mutants 1000 days after Tpeak, which can 
be assumed to be near equilibrium by comparing the means and variances of mutants 
1000 days after Tpeak [Table 4.13] to the equilibrium means and variances [Table 4.12], 
are calculated [Figure 4.12]. We observe that the triple mutant is unlikely ("-'0.0025 
probability) to exist in a patient prior to the treatment. The double mutants are present 
in about 97% of patients with counts ranging from 1 - 102 . 
Table 4.13 Mean±SD of mutants 1000 days after Tpeak· Parameters are set 
as in Table 4.2. 
Single mutants Double mutants Triple mutant 
23972.6859 ± 692.1636 13.6534 ± 14.7802 0.0074 ± 0.2945 
As comparison, we do another numerical example with the same parameter values as 
before except that ma= mb =me= 4 x 10-15 and~= 0.99, 1 ~ i ~ 7, which is quite 
favorable for the generation of the triple mutant. Mean±SDs at equilibrium under this 
setting are listed in Table 4.14. 
Table 4.14 Mean±SD of mutants at equilibrium with 
ma = mb = me = 4 X 10-5 and ~ = 0.99, 1 ~ i < 7. 
Other parameters are set as in Table 4.2. 
Single mutants Double mutants Triple mutant 
158752.5215 ± 3976.6802 1242.6154 ± 430.3124 14.5890 ± 50.3631 
The high fitness of mutants not only increases the equilibrium counts of mutants 
by one to two orders of magnitude, but also affects the timing of mutant appearance. 
At day 2000, mean and standard deviation are 158752.4192 and 3976.6773 for single 
mutants, 1242.6036 and 430.3092 for double mutants and 14.5879 and 50.3607 for the 
triple mutant, which are quite close to the means and standard deviations at equilib-
rium [see Table 4.14]. Thus we assume that the process reaches equilibrium by day 2000. 
Figure 4.13 shows mean±SD of the triple mutant during the first 2000 days after T peak 
(using the means in Table 4.10 as starting counts) and its marginal distribution 2000 
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days after Tpeak· From the distribution of triple mutant at day 2000, we infer that, un-
der this setting, approximately 50 percent of patients are expected to have one or more 
triple mutants present. Comparing the dynamics for the two fitness profiles {Figure 4.11 
and Figure 4.13), we see that although the high fitness of all mutants increases mean 
counts of mutants at equilibrium, as predicted in Figure 4.10, the rate of convergence 
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Figure 4.12 Distributions of double and triple mutants 1000 days after 
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Figure 4.13 Effect of high mutation rates and high fitness of mutants on 
the dynamics. ma = mb = me = 4 x 10-5 and R = 0.99, 
1 :::; i :::; 7. Other parameters are set as in Table 4.2. Upper 
graph shows the mean±SD of triple mutant during the late 
acute and chronic stage. Lower graph shows the distribution 
of triple mutant 2000 days after Tpeak. 
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4.3.3 Production of Resistant Mutants During Therapy 
We already know that there are two alternative causes of treatment failure due to 
resistance. It may be caused either by the existence of resistant mutants in the pa-
tient's virus population before the start of therapy or by the resistant mutants newly 
produced from the residual replication of wild-type drug-sensitive virus population as it 
declines during therapy. In this section we compare the likelihood of these two causes 
in the branching process framework. We make direct comparison between the abun-
dance of resistant mutants prior to treatment and the total number of resistant mutants 
newly produced during treatment. Tuactability of the branching process gives us elegant 
results. 
We begin with a simple model that contains only wild-type virus and resistant mutant 
I 
with a single point mutation at site a [Figure 4.14 (a)]. The time evolution of the counts 
of wild-type virus and mutant during drug therapy constitutes a two-type branching 
process. Particles are labeled by numbers as in Figure 4.14. ma is the point mutation 
rate at site a. We have defined effective reproductive numbers, Ri, for particles in the 
absence of drugs. Similarly, the dynamics of the system during drug therapy depends 
on the effective reproductive numbers, R~, during treatment. We define resistant viruses 
as those viruses with effective reproductive numbers, R~, larger than 1 in the presence 
of drugs. Usually resistant mutants have impaired fitness relative to wild-type virus in 
the absence of drug as we assumed in previous sections. Then for a resistant mutant, 
we have R~ > 1 > ~. Again we stress that the effective reproductive numbers are 
a combined property of host, virus and drug. In particular, the host environment is 
quite different pre- and post-treatment. Susceptible cell counts rise substantially on 
treatment such that the apparent fitness of mutants is enhanced on treatment. In reality, 
the mutants are expected to be intrinsically less fit both on and off treatment, i.e., 
they produce, on average, fewer offspring per infection. Because the values of effective 
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reproductive numbers, R~, depend on the susceptible cell counts, they undoubtedly 
change with time. However, for the sake of simplicity, it is assumed that on the time-
scale we are considering, the abundance of susceptible cells and immunity are constant, 
so effective reproductive numbers on this time-scale do not change. That is, the process is 
time-homogeneous. The implications of this time-homogeneity assumption are discussed 
in the conclusions. 
(a) 
Figure 4.14 A schematic illustration of the system with (a) one and (b) two 
point mutations between sensitive wild-type virus and resistant 
mutant virus. 
Suppose the system achieves equilibrium prior to the drug therapy. Then there is 
neq P IT0 in the body. P ITa is in balance between mutation and selection. As a trivial 
case of Eqs. (3.20) and (3.25), the mean and variance of P ITa at equilibrium are given 
by maneq/(l - Ri) and maneq/(l - Ri)2 . 
To compare the number of mutants P ITa produced de novo during treatment, we 
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assume that there is no P ITa present at the start of treatment. Once drug therapy is 
started, the effective reproductive number of wild-type sensitive virus R~ is driven below 
one. If the therapy is so successful that ~ = 0, then we are in the happy state that no 
new cells will be infected and hence no resistant virus can emerge. When 0 < R~ < 1, 
the population of P IT0 will be driven to extinction but some residual replication is still 
ongoing. The de novo production of resistant mutants during therapy is possible so long 
as there is residual replication. Note the impact of latent infection is not considered in 
this model. 
For the two-type branching process constituting PIT0 and PITa, the birth (µ) and 
death rates (>.) of the two particles are set as in Table 4.15. In this and the following 
derivations, we neglect back-mutation for the sake of simplicity, so the birth rate >. 10 is 
set to 0. Analytic results for considering back-mutations can also be derived but are too 
complicated to write down. 





It is trivial to set up the progeny generating functions, P0 (s) and P1(s), of the two 
particles according to formula (3.3). Taking partial derivatives of progeny generating 
functions, we get the matrix of progeny means 
F = [ (2~~~Rli ';:;£ l 
2R' ' 
0 ~ 
where the entry Fii = 8~.Pi(l),O ~ i,j ~ 1, is the mean number of daughter particles 
) 
of type j produced by a particle of type i, and the n matrix of the branching process 
n = c x [ (1 - ma)~ - 1 ma~ ] · 
0 R~ -1 
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Note the process is super-critical since R~ > 1. In order to account for the total number 
of P ITa generated de novo from wild-type sensitive virus P IT0 , we set R~ = 0 and make 
the process subcritical. Thus by formula (3.31) and under the reasonable assumption 
ma « 1, the matrix of average total descendants is 
[ 
l+RQ maR' l [ ~ A = (I - F)-1 = 1-(1-ma)RQ [1-(1-ma)RQJ(l-R].)(l+R].) ::::::: 1-RQ 
0 l+R]. 0 
1-R]. 
~1 1-RQ ' 1 
where A;, 0 ~ i,j ~ 1, has the interpretation that when the subcritical branching 
process starts with a single particle of type i, an average A; particles of type j will 




Bo = [1 - (1 - ma).Rfi]3 x 
[ 
H:i(l + R~)(4 - 3ma + maR:i - m~R:i) 
maR:i(2R:i - maR:i - maJl!i + 1 + R!(f) 
[ 
4RQ(l+{J>) maRQ(l+{!li)2 l 
,....., (1-RQ) (1-R0) 
,....., maRQ(l+R0)2 maRp 
(1-RQ)3 1-RQ 
maR:i(2R:i - maR:i - maJl!i + 1 + R!(f) ] 
maR:i(Jl!i- maJl!i + 3maR:i-2R:i + 1) 
Suppose at the start of treatment, there are neq wild-type P IT0 but no P ITa. Then 
upon usage of drugs, around neqmaR:i/(l-R~) ± Jneqma.Rfi/(l - Rf>) mutant P ITa will 
be generated de novo from P IT0 during the decline of population P IT0 . As comparison, 
neqma/(l-R1) ± Jneqma/(l -R1) PITa are expected at start of treatment [Table 4.11]. 
For example, if ma= 3 x 10-5 [Mansky et al. (1995)] and neq = 4 x 107 [Haase (1999)], 
the abundance of mutant prior to treatment and the number of mutants generated de 
novo with different values of R1 and R:i are listed in Table 4.16. We are interested in the 
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ratio, 8, of the number of P !Ta produced de novo from wild-type P IT0 during therapy 
to the number of the P !Ta present at the start of therapy. The mean and variance of 8 
can be approximated by the delta method [Casella et al. (2001) pp.244]. 
E(8) 
Var(8) ~ 
E(8), plotted in Figure 4.15, only depends on the fitness of mutant before treatment 
(R1) and the fitness of wild-type mutant in presence of drugs (Rh). When the wild-type 
virus is highly sensitive to the drug therapy (smaller R~) and the mutant has high fitness 
in the absence of drug (larger R1), the ratio 8 is much smaller than 1, implying that 
treatment failure is much more likely to be caused by preexisting resistance than the 
resistance produced de novo during therapy. This calculation is based on the assumption 
that the virus population has achieved equilibrium prior to drug therapy. If treatment 
is initiated earlier, fewer mutants are expected. 
Table 4.16 Mean±SD of mutants present before start of treatment and 
mean±SD of mutant generated de novo during treatment. 
I Ri 0 0.2 0.4 0.6 0.8 
I Before treatment 1200 ± 35 1500 ± 43 2000 ± 58 3000 ± 87 6000±173 
I ~ 0 0.2 0.4 0.6 0.8 





Let us suppose that the novel antiviral therapy used in Markowitz et al. (2003) 
totally shuts down viral replication, i.e., Rh = 0. Then the clearance rate of productively 
infected cells is estimated to be 0. 7 day-1. Previous studies estimated the clearance rate 
of productively infected cells to be"" 0.5 day-1. Thus we infer that previous treatments 
were not 100% effective, i.e., Rh > 0. Rh in previous treatments can be estimated as 
,...., (-0.5/0. 7+1) =rv 0.286. As we can see in Figure 4.15, for this value of R~, treatment 
failure is much more likely to be caused by preexisting resistant virus regardless of the 
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fitness of the mutant prior to treatment. However this estimate of R~ is a lower bound 
since the assumption of complete suppression in Markowitz et al. (2003) is optimistic. 
We can also compute the extinction probability of the preexisting virus population 
directly. Let x0 be the probability of extinction under drug therapy when there is only 
one P IT0 at the start of therapy and x1 be the probability of extinction under drug 
therapy when there is only one P !Ta at the start of therapy. Then x0 and x1 satisfy 
R ( ) _ 1 mxo[mx1 + (1- m)x0) 
Xo - 0 X - 1 + m + 1 + m ' (4.2) 
1 R' x2 
x1 = P1 (x) = 1 + Ri + 1 ~ ~i' (4.3) 
when neglecting back-mutation. Eq. (4.3) is easily solved to give x1 =1/Ri, which can 
be substituted into Eq. ( 4.2) resulting in a quadratic equation for x0 . Therefore when neq 
I 
PIT0 and maneq/(l - Ri) PITa are present at the start of therapy, the total extinction 
probability is x~eq x x~aneq/(l-Ri). Note when m = 0, i.e., replication of wild-type virus 
is totally shut down, Eq. ( 4.2) has no solution less than 1. In other words, extinction is 
certain when there is only wild-type virus present at the start of therapy. 
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Figure 4.15 Upper figure shows the dependence of the average ratio E(8) on 
the effective reproductive number R1 of P !Ta before t reatment 
and the effective reproductive number R~ of wild-type P IT0 
during treatment. Lower figure is the contour plot of E(8) . 
The contour plot elevation levels are 0.1 , 0.2, 0.5, 1, 2, 5, and 
10 from left to right. 
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Now we expand the model to consider resistant mutants that differ from wild-type 
virus by two point mutations [Figure 4.14(b)]. Let ma, mb be mutation rates at two 
associated sites a and b respectively and RL 0 $ i $ 3, be the effective reproductive 
number for type i particles during drug therapy. Still ignoring back-mutation, birth 
and death rates for each particle are set as in Table 4.17 and again the birth and death 
process is translated into a branching process model according to formula {3.3). We set 
R'a = 0 in order to compute the total number of particle 3 (PITab) generated de novo. 
The mean progeny matrix is 
RQ(2-m,.-mb) m,..RQ ~ 0 l+R-1, l+R-1, l+R-1, 
0 RJ.(2-mb) 0 mbRJ 
F= l+R) 1+.R) 
0 0 .R.{z(2-m,.) ~ 
1+~ 1+~ 
0 0 0 0 
through which we obtain the matrix for average total descendants 
~ m0 R;,(i+R;> m&R;,(1+~) ~(R' A) 1-RQ (1-n;,)(1-RD (1-n;,)(1-n;) 1-R(, 1-k~ + 1-R2 
0 l+R' 0 m&Rj 
A= (I - F)-1 :::::i 1-Rt 1-R1 
l+R' ma5 0 0 1-n; 1-n; 
0 0 0 1 
The variance of these counts are complicated to write. But again if we assume that the 
mutation rate for each site is the same and much smaller than unity, ma = mb = m « 1, 
and that all intermediate mutants have the same effective reproductive number as wild-
type virus during treatment, Rf>= R~ = R1i = R'. Then the variance of the number 
of resistant mutants PITab descendent to a single ancestor PIT0 , PITa or Pin is 
B0 (3,3) = 2m2R12/(1- R')2 and B1(3,3) = B2(3,3) = mR'/(1- R') respectively. 
Now we consider how many PIT ab are present at the start of treatment. neq is the 
count of wild-type P IT0 at equilibrium prior to treatment. Let TJ = [maCneq, mbCneq, 0) 
be the vector of immigration rates at equilibrium. Then the mean counts of P !Ta, P !Tb 
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Table 4.17 Birth rates and death rates of particle 0 to 3. 
µo c µ1 c 
Aoo (1-ma)C~ .A10 0 
.A01 maC~ .An (1- mb)CR~ 
.Ao2 mbC~ .A12 0 
A03 0 A13 mbCR~ 
µ2 c µg c 
.A20 0 A30 0 
.A21 0 A31 0 
.A22 (1-ma)C.m A32 0 
A23 mac.m A33 CR'g 
and PIT ab at equilibrium are 
with variance/covariance matrix 




m 2ne R m 2negR 2m2negR 
2c1-A>a 2(1-R)3 (1-R)3 
if ma = mb = m «: 1 and R1 = R2 = Rg = R. Then to compare the number of P !Tab 
produced de novo during treatment to the pretreatment abundance of PIT ab, we again 
can form the ratio 8 2 and approximate E(82) and Var(82) by the delta method. 
The model can be expanded to consider resistant mutants that differ from wild-type 
virus by n point mutations. For simplicity, we assume that the mutation rates for each 
site are the same, m, and much less than unity, all mutants have the same effective 
reproductive number, R, prior to treatment and all intermediate mutants have the same 
effective reproductive number, R', as wild-type virus during treatment. Then means and 
variances of the number of different mutants existing prior to treatment and the means 
and variances of the number of de novo produced resistant n-mutants descendent to a 
preexistent wild-type virus or a preexistent intermediate k-mutant can be calculated and 
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k'n ( R )k are shown in Table 4.18. For example, ·Req ~R ± ~ ( mR )k k t t . t t R(l-R) l-R -mu an exis s a 
the start of treatment and each of the preexisting k-mutant will finally produce about 
(n - k)! (~1;;,, r-k ± J(n - k)! (~1J:., r-k resistant n-mutants during treatment. Note 
for each class of k-point mutants, there are (~) strains. Thus, by the delta method, the 
mean of the total number of resistant n-mutants produced de novo during treatment 
from preexisting wild-type and intermediate mutants is approximately 
neqn! ( 1~~') n + E (~) k!~eq c~~) k. (n - k)! ( l~R~I) n-k 
_ ! ( mR' )n n!neqmn n-1 (_!!:__)k (_!!_)n-k 
neqn 1 - R' + R L 1 - R 1 - R' 
k=l 
(4.4) 
Table 4.18 Means and variances of mutants present prior to treatment (left table) and 
means and variances of the number of de novo generated resistant mutants 
descendent to a preexistent mutant (right table). 
Mutant Mean Variance Mean Variance 
0 0 ( R')" ( R')" neq n! ::R' n! l":_R, 
1 mne9 ~ ( R' r-1 ( R' r-1 1-R ) (n -1)! ::R' (n - 1)! ::R' 
2m2 n.fR 2m2 n.fR ( R' r-2 ( r-2 2 (n - 2)! ::R' (n - 2)! ;:~, (1-R 2 (1-R 3 
k k!ne9 ( mR) k R 1-R 
k!ne ( mR) k 
R(l-h) 1-R 
( r-k (n - k)! ;:~, ( r-k (n-k)! ~~I 
( r-2 ( r-2 ( mR' ) 2 ( mR' )2 n-2 (n-2)!ne9 mR (n-2)!n.9 ..!!!li R 1-R R(l-R) 1-R 2 1-R' 2 1-R' 
( r-1 ( r-1 n-1 (n-l)!n.9 mR (n-l)!ne9 mR mR' mR' R 1-R R(l-R) 1-R I=1F 1-R' 
n!ne9 ( mR)n n!n. ( mR) n 0 0 n R 1-R R(1-fo 1-R 
Dividing ( 4.4) by the average number of resistant mutants present prior to treatment, 
(n!neq/R)[mR/(l - R)]n, we get an estimate (by the delta method) of the mean of the 
ratio of resistant mutants produced during therapy to their abundance at the start of 
therapy 
{ 
1-R [R' R( R'(l-R) )n] 





E(8n) for n = 1, 2, 5, 10 is plotted in Figure 4.16. E(8n) depends only on the fitness 
of mutants prior to treatment, R, the fitness of the sensitive wild-type and intermediate 
mutant virus during treatment, R', and n. It is independent of the mutation rate m 
and the clearance rate of productively infected cells C. When R' > R, E(8n) increases 
geometrically with n; when R' < R, E(8n) decreases geometrically with n. From the 
graph, for n 2'.: 2, resistant mutants are more likely to be generated (for the first time) 
de novo during therapy than to preexist when R' > R. 
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Figure 4.16 Left column shows dependence of the average ratios E(8n) on 
the effective reproductive number R of all mutants before treat-
ment and the effective reproductive number R' of wild-type and 
intermediate mutant virus during treatment for n = 1, 2, 5, 10. 
Right column shows contour plots of E(8n) for n = 1, 2, 5, 10. 




The success of drug therapy depends to a large extent on whether or not resistant 
virus is present in patients prior to treatment. Based on a multitype continuous-time 
branching process model for the mutant populations, we calculate statistics and distribu-
tions of the process from the start of acute infection to the equilibrium state during the 
chronic stage. The variability in the abundance of mutants generated can occur by ran-
dom fluctuation. It also depends crucially on the dynamics of the wild-type population 
P IT0 , as well as the mutation rates and mutant fitness picture. 
During the early acute stage (first few weeks after start of infection), the number 
of single mutants increases exponentially as the surrounding P IT0 population grows. 
At the end of the early acute stage, single mutants are well represented on the order 
102 - 104 . The abundance of single mutants depends greatly on the dynamics of P IT0 . 
For example, when the population P IT0 increases from the starting inoculum of 10 to 
peak load 107 in 10 days, the average number of single mutants at day 10 is on the order 
of 102, while when P IT0 increases from 10 to 108 in 10 days, the mean number will be on 
the order of 104 • Double mutants may or may not be present. The chance that any double 
mutant is present at the end of the acute stage is approximately 0.2949 [Figure 4.4] in 
the typical numeric example of Table 4.2 and approximately 0.9978 [Figure A.6] in a 
setting extremely favorable for the generation of mutants. The triple mutant has little 
chance to occur during this stage as shown in a variety of conditions. The probability, 
e(t), that no mutants are present drops rapidly from 0.95 to 0.05 in a short period of only 
a few days. The timing of this period is determined by various factors, with significant 
influence from the starting inoculum. The larger starting inoculum of P IT0 , the faster 
mutants appear. Mutants with more point mutations appear slower. 
In the late acute and chronic stages, the amount of wild-type P IT0 and mutant 
viruses will converge to equilibrium. The average equilibrium frequency of mutants 
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relative to the equilibrium level of P IT0 depends on the mutation rates at associated 
sites and fitness of intermediate mutants. For example, with all the mutation rates equal 
to 3 x 10-5 per base per replication cycle, the frequency of triple mutant may vary by 
several orders of magnitude with different combination of the intermediate single and 
double mutants fitnesses are used [Figure 4.10]. Means and variances of mutants at 
equilibrium can be calculated analytically. The distribution of mutants at equilibrium 
may be approximated by calculating the distribution at a time when the process is 
considered to have converged to equilibrium. For the numeric example in Table 4.2, we 
expect to find 23973±693 single mutants, 14±15 double mutants and,...., 0 triple mutant 
at equilibrium. The chance that no double mutant is present at equilibrium is small, 
approximately 0.03. The chance that any triple mutant is present at equilibrium is still 
near 0. The counts of mutants at equilibrium increase with higher mutation rates and 
mutant fitness. In the numeric example in Figure 4.13, triple mutants are expected to be 
present in about 10 percent of patients at equilibrium. However the rate of convergence 
to equilibrium is slowed with higher mutant fitness. 
There are some practical implications for the clinical treatment. The preexistence 
of resistant mutants depends on the number of point mutations required to confer full 
resistance. For monotherapy, to which one or two point mutations can confer resistance, 
the early high abundance of single mutants will cause rapid selection of resistant virus 
and lead to therapy failure. Based on the characterization of "extinction probability" 
during the first stage, only monotherapies starting in the first few days or hours can 
be assured of success. The resistance profile of drug therapy should be considered even 
very early in disease. The length of time for safe initiation of monotherapy depends on 
the growth characteristics of P IT0 • Resistance to two or three drugs may require several 
point mutations. If resistance requires three or more point mutations, resistant mutants 
have virtually zero probability of appearing prior to treatment. Under these conditions, 
increasing the efficacy of drug (for example by increasing the dosage) is an effective way 
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to control the virus. 
To discriminate the two possible causes of resistance-related treatment failure, we 
compare the number of resistant mutants generated de novo during treatment and the 
preexistence of resistant mutants. Again this depends on the number of point mutations 
required for resistance. For resistance conferred by single mutants, treatment failures 
are more likely to be caused by preexisting resistant mutants when R~ < 0.5, while 
for resistance requiring more than two point mutations, the source of treatment failure 
depends on the fitness of mutants in the absence of drugs and the fitness of wild-type 
virus and intermediate mutants in presence of drugs. 
For ease of calculation, we have assumed that the effective reproductive numbers 
of wild-type virus and mutants are constant during treatment, i.e., the process is time-
homogeneous, an assumption that may not hold in reality. For instance, with the decline 
of wild-type virus upon treatment, the susceptible cell count may increase substantially 
and improve the fitness (effective reproductive number) of virus. In this situation, if we 
assume that the starting conditions are applicable throughout treatment, we obtain a 
best case for the patients. Vice versa, if we use the on-treatment equilibrium conditions, 
we can get the worst case scenai;io for patients. Thus, with more precise data on fitness 
during treatment, we could bound the results from above and below. 
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Figure A.I Sensitivity to starting inoculum of PIT0 • Upper figure shows 
dependence of mean behavior on the starting inoculum n0 of 
P IT0s. From left to right are the mean number of single mu-
tants for n0 = 1000, 500, 100, 10, 1 respectively. In all cases, the 
mean number of double and triple mutants remain close to 0. 
Lower graph shows the "extinction probability" e(t) in the same 
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Figure A.2 Sensitivity to peak load of P IT0• Upper graph shows the de-
pendence of mean behavior on the peak load npeak of P IT0s. 
From left to right are the mean number of single mutants for 
npeak = 10, 5, 1, 0.5, 0.1x108 respectively. In all cases, the counts 
of double and triple mutants remain close to 0. Lower graph 
shows "extinction probability" e{t) in the same settings. Other 
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Figure A.3 Sensitivity to the time to peak load npeak· Upper graph shows 
the dependence of mean behavior on the length of time period 
to reach peak load of PIT0 . Tpeak = 5, 10, 15, 20, 25, 30 respec-
tively. The counts of double and triple mutants remain close 
0 throughout this stage. Lower graph shows e( t) in the same 
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Figure A.4 Sensitivity to mutation rates A. Upper graph shows the mean 
behaviors of single mutants when ma = mb = me = 3 x 10-5 
and ma = mb = me = 4 x 10-5 respectively. Other parameters 
are set as in Table 4.2. The counts of double and triple mutants 
stay near 0 throughout this stage in both cases. Lower graph 
shows the time evolution of "extinction probabilities" e(t) in 
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Figure A.5 Sensitivity to mutation rates B. Mean behavior of single mu-
tants when ma = 4 x 10-5 and mb = me = 3 x 10-5. The counts 
of double and triple mutants stay near 0 throughout this stage. 
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Figure A.6 Sensitivity to fitness profile of mutants A. Marginal dis-
tributions of double and triple mutants at day 10. 
Ri = 0.99, 1 :S i :S 6 and R1 = 0.85. Other parameters are 
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Figure A.7 Sensitivity to fitness profile of mutants B. Marginal distributions 
of double and triple mutants at day 10. Ri = 0.50, 1 ::; i ::; 6 
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Figure A.8 Sensitivity to fitness profile of mutants C. "Extinction proba-
bilities" e(t) under three different fitness profiles in [Table 4.9]. 
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